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THE FUNCTION OF ERBIN, A SCAFFOLD PROTEIN, AS A TUMOR 
SUPPRESSOR IN COLON CANCER 
 
 
Erbin belongs to the LAP (leucine-rich repeat and PDZ domain) family of scaffolding 
proteins that play important roles in orchestrating cell signaling. Here, we show that Erbin 
functions as a tumor suppressor in colon cancer. Analysis of Erbin expression in patient 
specimens reveals that Erbin is downregulated at both mRNA and protein levels in tumor 
tissues. Functionally, knockdown of Erbin disrupts epithelial cell polarity and increases 
cell proliferation in 3D culture. In addition, silencing Erbin results in an increase in the 
amplitude and duration of signaling through Akt and RAS/RAF pathways. Moreover, 
Erbin-loss induces epithelial-mesenchymal transition (EMT), which coincides with a 
significant increase in cell migration and invasion. Erbin interacts with KSR1 and displaces 
it from the RAF/MEK/ERK complex to prevent signaling propagation. Furthermore, 
genetic deletion of Erbin in Apc knockout mice promotes tumorigenesis and significantly 
reduces survival. Tumor organoids derived from Erbin/Apc double knockout mice have 
increased tumor initiation potential along with increased Wnt target gene expression as 
seen by qPCR. Collectively, the studies within this dissertation identify Erbin as a negative 
regulator of EMT and tumor progression by directly suppressing Akt and RAS/RAF 
signaling in vivo. 
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CHAPTER 1: INTRODUCTION 
1.1 Signaling Activation in Colorectal Cancer 
 Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the 
United States. Approximately 135,000 new cases and 50,000 deaths are predicted for the 
year 2017 [1]. According to the United States Centers for Disease Control (CDC), data 
from 2014 shows the state of Kentucky has the highest rates of CRC incidence in the nation 
(49.4 persons per 100,000 after age-adjustment), which is a great incentive for myself and 
the Gao laboratory to study this disease at the University of Kentucky. Additionally, rates 
of CRC outside of the United States have been dramatically increasing with worldwide 
incidences currently around 1.2 million annually, drastically increasing the importance for 
studying this disease [2].  
 While incidence rates of CRC are increasing, mortality from this disease is 
predominantly due to metastasis to other organs. The patients diagnosed with early stages 
of colorectal cancers are treated effectively with surgical resection followed by adjuvant 
therapy; such as 5-FU, Irinotecan, or Oxaliplatin. Currently, targeted therapies such as 
Avastin and Cetuximab are reserved for second line therapies, while immunotherapies have 
thus far shown little promise in CRC. However, while treatments have been shown to be 
effective for early stage CRC patients, ultimately almost half of all patients diagnosed with 
CRC will develop disseminated advanced disease which in most cases will be fatal due to 
poor responses to available treatment options [3]. Understanding the progression of this 
disease, particularly the mutations involved in late stage metastatic CRC, will allow us to 
develop necessary treatment options to improve the overall survival of CRC patients. 
 Over the last thirty years, the risk factors for the development of CRC have been 
studied at both the population and molecular levels. The development of CRC is 
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multifactorial, as with many cancer types, involving a combination of environmental 
factors and genetic predispositions. Several studies have shown that lifestyle choices (many 
of which are common in the state of Kentucky) such as smoking, alcohol abuse, obesity 
and physical inactivity, and high fat diets can increase the risk of developing CRC [4, 5]; 
with other studies showing that diseases such as inflammatory bowel disease can increase 
CRC risk [6]. Other genetic risk factors include the autosomal-dominant genetic disorder, 
Familial Adenomatous Polyposis (FAP) which results in the formation of many colon 
adenomas early in a patient’s life, often presenting the late teenage years or twenties [7, 8]. 
 While the risk factors that increase the chances of developing CRC are 
multifactorial, the genetic mutations that occur as this disease progresses have been 
extensively investigated. Initially hypothesized by Fearon and Vogelstein in 1990 [9], there 
seems to be a particular order in which certain genes mutate as CRC initiates and progresses 
to a more malignant tumor type. This stepwise progression from normal epithelia of the 
colon to a transformed malignant carcinoma is often accompanied by and a result of 
chromosomal instability (CIN) as indicated by the frequent occurrence of chromosomal 
alterations and loss of heterozygosity (LOH) [10, 11]. Alternatively, the CIN pathway of 
malignant transformation may occasionally be referred to as the “suppressor pathway” to 
CRC. 
 The first observed mutation in the CIN pathway that results in the initiation of CRC 
is most often in the Wnt signaling pathway. This is the same pathway that was also 
identified to be mutated in a majority of familial FAP cases [12] and has been implicated 
in CRC that results from obesity and lack of exercise [13]. Several proteins within the Wnt 
pathway can be mutated and ultimately result in increased signaling. As shown in Figure 
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1.1, the most common mutations occur in the APC gene. Also, for this reason, the most 
commonly used mouse model to study CRC in vivo uses an intestinal specific knockout of 
Apc, resulting in hyperproliferation of the intestinal epithelia and the formation of 
adenomas. 
 Under normal, non-stimulated conditions, the APC protein interacts with Axin and 
β-catenin, along with other members of the destruction complex indirectly, and is 
responsible for degradation of β-catenin (Figure 1.2) [14]. Upon Wnt activation of the 
Frizzled receptor the proteins that comprise the destruction complex translocate to the 
plasma membrane, resulting in β-catenin stabilization and subsequent translocation to the 
nucleus where transcription is activated [15, 16]. APC mutations result in a loss of function 
and effectively mimic Wnt stimulated signaling, increasing cytosolic β-catenin and 
eventually leading to increased translocation of β-catenin to the nucleus and increase in 
Wnt pathway transcriptional targets such as T-cell factor (Tcf) and lymphoid enhancer 
factor (Lef). Figure 1.2 shows protein interactions that are responsible for signaling under 
both basal and Wnt stimulated conditions. 
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Figure 1.1 Frequency for each genetic mutation found in colorectal cancer 
Recurrent somatic gene mutations that are found in human CRC, including the percentage 
of total tumors that harbor each mutation. 1 Frequency observed in all sporadic colon 
cancers. * associated with mismatch repair (MMR) defects. [17]  
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Figure 1.2 General activation of Wnt signaling 
APC is a member of the destruction complex as pictured in basal conditions. In this 
condition β-catenin is phosphorylated and subsequently ubiquitinated and degraded 
through the proteasome pathway. Upon Wnt stimulation Dishevelled is recruited to the 
active Frizzled receptors where it facilitates the interaction between the phosphorylated 
LRP5/6 and Axin [18]. Other proteins that comprise the destruction complex are also 
translocated to the active receptor and thus are removed and sequestered away from β-
catenin [15, 19]. β-catenin is no longer degraded and translocates to the nucleus stimulating 
expression of Wnt target genes. Adapted from Dunn et al. [20]  
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 More recently, several other proteins have been found to modulate Wnt/APC 
signaling adding to the complexity of this pathway. The identification of receptors LGR-4 
and LGR-5, which are stimulated by the extracellular ligand R-spondin, can significantly 
increase Wnt signaling upon activation [21]. This activation can be further enhanced by 
the activation of a co-receptor, LRP6, a protein that is activated through cytoplasmic 
phosphorylation and results in amplification of Wnt signaling [22]. Understanding the 
dynamics of how these proteins may alter Wnt signaling in different cancer types is still 
ongoing.  
 The functional effects of Wnt signaling activation are well conserved through 
evolution and Wnt pathway components play an important role in organismal patterning 
during development [23]. Outside of development, one of the key roles of Wnt signaling 
is in adult stem cells. This role is particularly important in tissues that have higher rates of 
self-renewal, which include mesenchymal stem cells in bone marrow, hair follicles, and 
intestinal stem cells in the crypts [24-26].  However, sporadic CRC formation requires loss 
of APC function in both alleles [27] and is often observed as an increase in proliferation 
and the formation of neoplasia within the colon. This increase in tumorigenesis and 
proliferation has been attributed to an evasion of cell death through the increased activation 
of Cyclin D1 after APC mutation [28], as well as more complicated mechanisms which 
include changes in Wnt signaling resulting in alterations to intestinal stem cells and tumor 
initiating cancer stem cells [29, 30]. Current studies are focused on further determining the 
molecular mechanism underlying CRC tumor initiation and activation of cancer stem cells. 
 The next gene that is frequently mutated in the stepwise progression of CRC is the 
proto-oncogene KRAS (Figure 1.1 and 1.5). These mutations, with more than 90% 
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occurring within exon 12 or 13, lead to further evasion from apoptosis and often coincide 
with an increase in proliferation [31]. A less common mutation within the same pathway 
is that of BRAF, while mutually exclusive to KRAS mutations, both result in an increase 
in the mitogen-activated protein kinase (MAPK) (Figure 1.3) [32]. Simultaneous increases 
in Wnt signaling and MAPK, as well as AMP-activated protein kinase (AMPK), have been 
observed in CRC with mutated KRAS suggesting interactions between these pathways can 
occur and changes in signaling may alter the prognoses of CRC patients [33, 34]. 
Understanding the mutations and alterations in protein interactions within the MAPK 
pathway in CRC are necessary to help understand how this pathway results in increased 
proliferation and crosstalk between signaling pathways. As MEK inhibitors are currently 
being tested as second line therapies to treat patients with KRAS mutations, a more in depth 
knowledge of protein interactions and scaffold proteins involved in this pathway is 
necessary for more precise treatments. 
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Figure 1.3 Signaling through the PI3K/Akt and ERK/MAPK pathways 
A schematic of the signaling that occurs in two of the most mutated pathways in CRC. 
Following a mutation in the APC signaling pathway, mutations in PI3K and either RAS or 
RAF, and to a lesser extent at the receptor level, allows the cells to increase transcription 
for pro-growth and anti-apoptotic proteins.   
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 In addition to activation of Wnt and MAPK pathways, there are several mutations 
that may further the malignant progression of CRC (Figures 1.1 and 1.5). As with many 
types of cancer, late stage CRC often acquires a mutation in TP53 that results in a loss of 
function in this important tumor suppressor. This mutation results in further avoidance of 
the apoptotic pathway and thus increases sustained proliferation [35], and often occurs 
simultaneously with the loss of p53 is LOH of the 18q chromosome [36]. Additional genes 
that are contained within this long arm of the 18th chromosome encode for Smad2, Smad4, 
and Deleted in Colorectal Carcinoma (DCC). Additionally PHLPP1, a phosphatase that 
has been shown to act as a tumor-suppressor in CRC is localized to this region. This 
phosphatase has been shown to directly dephosphorylate both RAF1 and Akt, inhibiting 
cell motility and proliferation [37-39]. Importantly, several studies have shown that 18q 
LOH is associated with increased metastatic potential and decreased patient survival time 
[40, 41].  
 Lastly in the CIN pathway to CRC, mutations can occur in PI3KCA, the catalytic 
subunit of phosphoinositide-3 kinase (PI3K), in tumors with APC mutations (Figures 1.1 
and 1.5) [42]. The addition of this mutation leads to upregulation of Akt signaling which 
increases cell proliferation (Figure 1.3) [43]. Indeed, expression of a constitutively active 
PI3K in mouse intestinal epithelium results in an increase in tumor number and size [42]. 
As another potential target for pharmacological inhibition, more studies on the PI3K 
pathway and its crosstalk with the RAS/RAF pathway, would improve our ability to treat 
patients that harbor PI3K mutations.  
 Another aspect to consider when examining the progression of CRC is the 
microsatellite instability (MSI) status of the tumor. Approximately 15% of CRC have MSI, 
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which results from a loss of function in DNA mismatch repair (MMR). This DNA 
proofreading system is responsible for recognizing and repairing single nucleotide 
mismatches that are not recognized as errors by DNA polymerase. Ultimately, loss of 
function of these proteins reduces the fidelity at which cells replicate which in turn causes 
an increase in mutational burden and ultimately results in tumors with greater than a 100-
fold increase in mutations [44]. Most CIN pathway CRC tumors are MSI negative, while 
many tumors that result from genetic predisposition are positive for MSI. In addition to 
differences in the mutations and type of patients that are MSI positive, MSI status can alter 
a patient’s prognosis. MSI positive CRC tumors are more likely to occur in the proximal 
colon, have a medullary phenotype as determined by immunohistochemical (IHC) staining, 
and occur with lymphatic infiltrations of the tumor. Together, these differences result in a 
longer patient survival time and better prognosis than a patient with a more traditional CIN 
progression [45]. For these reasons there has been a more recent push to categorize CRC 
patients into specific sub-categories based upon their unique tumor mutations (Figure 1.4). 
These subtypes of CRC, called consensus molecular subtypes (CMS), can be used to 
monitor patient responses and may eventually prove useful for guidance in personalized 
medicine and individual prognoses [46].  
 The transformation process from normal epithelial cells to benign hyperplastic 
growth, to adenoma, and finally to carcinoma results from an accumulation of mutations 
(Figure 1.5). These mutations typically occur within a particular order and result in a well-
established stepwise progression of CRC. Confirming the requirement of this stepwise 
process in vitro, recent publications have used either sh-RNA or CRISPR/Cas9, in mouse 
or human intestinal stem cells respectively, to decipher the contribution of mutations in 
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individual genes within the CIN pathway. Normal human intestinal organoids grown in 3D 
culture were able to transform into tumor organoids after the reduction or mutation of only 
4 genes, APC, P53, KRAS, and SMAD4 [47-49]. Since the most common mutations 
observed in the CIN process alter cellular signaling events it is desirable to target these 
pathways in developing future treatments. Additionally, as systemic metastasis of CRC 
remains the single largest impediment for achieving better overall survival, additional 
studies and a better understanding of late stage signaling and molecular events leading to 
cancer metastasis are needed in order to improve the current treatment and prognoses of 
CRC patients.   




Figure 1.4 Gene expression-based molecular subtypes of colorectal cancer  
Consensus molecular subtypes (CMS) are a relatively new concept in identifying various 
subtypes of CRC based upon the genes that are found to be mutated during tumor molecular 
sequencing. Additionally, after sub-grouping of the tumors, these CMS can be used to 
monitor patient response and may prove useful for guidance in personalized medicine [46].   




Figure 1.5 Summary of the most frequent mutations occurring in the progression of 
CRC 
Originally proposed by Fearson and Vogelstein, the stepwise progression from normal 
epithelium to carcinoma has been refined over the past twenty years. We now know that 
most of all CRC tumors initiate with a Wnt pathway mutation, then gain a mutation in the 
ERK pathway, followed by additional mutations after the genome is significantly less 
stable. Image modified from basicmedicalkey.com [50]  
  14 
1.2 The Role of Scaffold Proteins in Signal Transduction 
The majority of the mutations that occur in the CIN pathway in CRC are 
components of signal transduction pathways that are involved in regulating cell growth. 
While many of these common oncogenic CRC mutations have been explored for several 
decades we are only more recently beginning to understand the intricacy of regulating 
multiple steps within and crosstalk between pathways.   
The organization of protein interactions and coordination of signaling are 
imperative for homeostasis. The proper trafficking and activation of receptors, including 
the oncogenic receptor tyrosine kinase (RTKs), is necessary to maintain normal epithelial 
cell signaling and preventing tumorigenesis. Activation of these receptors initiate signaling 
through pathways that control a variety of transcriptional programs including those that 
modify proliferation, differentiation, and cell apoptosis [51, 52]. Aberrant activation, 
occasionally through mutations (Figure 1.1), of these receptors can result in many diseases 
including cancer. Many different proteins can interact with these receptors, primarily on 
their cytoplasmic tails that are phosphorylated, including those with Src homology two 
(SH2) and phosphotyrosine-binding (PTB) domains [53, 54]. Interactions with an 
assortment of adapter proteins potentially allows a single receptor to alter which 
downstream pathways are activated depending on which adapter proteins are present or 
recruited at the time of ligand activation. For example, the association of Grb2, an adaptor 
that contains a SH2 domain, with the phosphorylated C-terminal tail of an activated RTK 
can recruit additional proteins such as guanyl nucleotide exchange factor (SOS) to the 
plasma membrane. Once SOS is in close proximity to RAS, RAS binds GTP and thus 
facilitates activation of the MAPK pathway [54, 55].  This manner of activating signaling 
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pathways is conserved from Caenorhabditis elegans, with LET-23 activation of RAS, to 
the ErbB family of receptors in humans. In addition to phosphorylation-mediated 
transduction of extracellular signals, a family of so called “scaffolding proteins” are 
involved in facilitating signaling propagation and they are partly responsible for the 
observed complexity in oncogenic cell signaling.  
Scaffolding proteins can alter receptor initiated signaling by changing the location 
of these receptors, such as helping them localize to the plasma membrane or to a specific 
domain within that membrane. Additionally, increasing evidence has suggested that the 
spatial and temporal regulation of signaling pathways require the assembly of tightly 
controlled signaling complexes that are organized by scaffolding proteins [56]. One 
example, PICK1, interacts with ErbB2 through a PDZ domain and facilitates ErbB2 
receptor clustering, resulting in more efficient signaling activation and receptor 
internalization [57]. In addition to adaptors and scaffolds that interact at the receptor level, 
there are also many scaffolding proteins that facilitate protein interactions downstream of 
the receptors. In the RAS/RAF pathway several pro-signaling scaffolds are known to 
increase the interactions of signaling proteins at different steps, increasing their ability to 
phosphorylate the next protein in the cascade. One example is that of Shoc2, a cytosolic 
protein that is targeted to late endosomes upon EGF-stimulation and positively regulates 
RAS-mediated signaling [58, 59].   
In addition to positive regulation of signaling pathways through scaffold proteins 
there have been a number of publications that have identified negative regulators. It is 
believed that these inhibitory proteins may act as a counter balance to their pro-signaling, 
often proliferation inducing, scaffold counterparts. Sprouty, found in Drosophila, and its 
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mammalian homologue Spred both act to suppress signaling through the ERK pathway 
[60, 61]. These negative regulating scaffold proteins alter the ability of RTKs to recruit the 
appropriate adapter proteins [62], and act as negative feedback regulators helping to 
diminish over-amplified signals. 
Certain protein-protein interactions, like those that help to facilitate the role of 
Shoc2 and Sprouty in altering cell signaling, are required in order for scaffold proteins to 
effectively promote or inhibit downstream signaling. Many scaffold proteins contain what 
are referred to as modular interaction domains and each scaffold may contain multiple 
interacting domains to allow the formation of multi-protein complex. Adding additional 
complexity, the protein-protein interaction domains within a scaffold protein may have the 
flexibility for bind several distinct ligands. It is possible for these domains within scaffold 
proteins to recognize peptide sequences (ie. PDZ, PTB, SH3 domains), other protein 
domains (ie. PyD, SAM, PB1 domains), or post-translational modifications (ie. SH2, 
Bromo, WW domains) [63]. Using a combination of these domains allows a cell to 
precisely modulate an intricate network of protein interactions and adjust these interactions 
to facilitate a desired downstream event.    
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1.3 Erbin Distribution and Function in Epithelial Tissues 
In addition to Sprouty and Spred, another protein that was found to disrupt the ERK 
signaling pathway is Erbin. Erbin is a member of the leucine-rich repeat (LRR) and PDZ 
domain (LAP) protein sequence superfamily. The members of this protein family are 
evolutionarily conserved, from Xenopus tropicalis, to Drosophila melanogaster, to Homo 
sapien, and all share somewhat similar domain structures (Figure 1.6). Erbin contains 16 
LRRs followed by a single PDZ domain at its C-terminus. LRRs are repeating amino acid 
sequences, generally 20-29 residues long, which assemble into superhelical structures and 
form a solenoid protein structure [64, 65]. Additionally, most LRRs are involved in the 
process of protein-protein interactions and maintain similar overall properties including a 
horseshoe-like shape and parallel beta-sheets on the concave side that are responsible for 
protein interactions [66]. The other domain of Erbin, the PDZ domain, is also involved in 
protein-protein interactions. These domains are about 90 amino acid residues in length 
which consistently fold into a beta-barrel that is comprised of 6 beta-strands and is most 
often capped by two alpha helices [67]. Functionally, the PDZ domain interacts with a 
specific peptide sequence located at the C-terminal tail of other proteins [68]. Together, 
these domains allow Erbin to interact with several proteins and possibly more than one at 
a given time.  
Other members of the LAP protein family include Scribble, Densin-180, and Lano 
in mammals [69, 70]. Functionally, LET-413, another member of the LAP protein family 
which is only expressed in Caenorhabditis elegans has been shown to control epithelial 
cell polarity, while Scribble has been shown to regulate polarity in both Drosophila 
melanogaster and in mammals [71]. Erbin, described as the mammalian homologue to 
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LET-413 and is structurally very similar to other LAP proteins, may also play a role in 
maintaining the polarity of epithelial tissues in addition to regulating ERK signaling.   
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Figure 1.6 Phylogenetic Tree and Domain Structure of LAP Proteins 
(A) A phylogenetic tree of LAP proteins, visualizing the divergence and evolutionary 
history of this proteins superfamily. Distance between proteins approximate sequence 
similarity. (B) Models that represent the common domain composition of LAP proteins 
that are used to facilitate protein-protein interactions. Erbin is most similar in identity to 
Densin-180, dLAP1, and LET-413. Adapted from Santoni et al. [72].   
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Erbin is located on the long arm of chromosome 5 and has several splicing variants 
[73]. Erbin mRNA is comprised of 26 exons and alternative splicing can lead to several 
alterations in the linker region of Erbin (between the LRR and PDZ domain) as well as 
variants that lack the PDZ domain entirely. Erbin RNA expression peaks during G2/M 
phase [74] and Erbin was also found to be present in most human and mouse tissues as 
detected by a 7.2-kb transcript and Western blot analysis detected Erbin in the brain, liver, 
kidney, spleen, intestine and skeletal muscle [73].  
Erbin was first identified by Dr. Jean-Paul Borg’s group in 2000 in an attempt to 
elucidate the protein-protein interactions necessary to organize signaling downstream from 
the ErbB2 receptor tyrosine kinase [75]. Erbin, specifically the PDZ domain, was found to 
interact with the amino acids at the C-terminal tail of the ErbB2 receptor, but interestingly 
not with any other ErbB family members. Conversely, no other PDZ domain interacts with 
the C-terminal tail of ErbB2, suggesting that this interaction is unique. This was of 
significance because other PDZ containing proteins can share up to 70% homology with 
the PDZ domain of Erbin but lack an interaction with ErbB2. Initially the authors in this 
publication attributed the unique binding affinity to the linker region since this region 
varies greatly between LAP proteins. However, later studies suggest that Erbin’s PDZ 
domain is in fact structurally unique and could also help specify unique ligands [75]. 
Following the identification of Erbin as an ErbB2 receptor interacting protein, the authors 
characterized the functional consequences of this interaction. One of the main findings of 
this initial publication is that Erbin co-localizes with ErbB2, and is required to localize the 
ErbB2 receptor to the basolateral membrane of epithelial cells. This localization is 
necessary for ErbB2 to carry out its normal physiological functions [76].  
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In addition to this localization, proper orientation on the plasma membrane would 
be required to receive activation from extracellular ligands, especially with the ErbB2 
receptor which is known as an orphan receptor and requires dimerization with another 
basolaterally localized ErbB family member to signal [77-79]. Furthermore, the authors 
showed that phosphorylation of ErbB2 upon activation allowed ErbB2 binding with a Src 
homology and collagen protein (SHC) and drastically reduced Erbin/ErbB2 interaction. 
Interestingly, this study also showed phosphorylation of an Erbin tyrosine residue, 
however, no functional experiments were performed in order to explore the consequences 
of this phosphorylation event [73]. Further proteomic studies have identified more potential 
Erbin phosphorylation sites through the combination of genetic and peptide-capture 
approaches. Erbin was identified as a new substrate of AMPK and two possible sites for 
AMPK phosphorylation were found in Erbin (S915 and S1079); however, no functional 
changes have been associated with these phosphorylation events [80]. 
Since the first identification of Erbin, there have been several publications that have 
helped to clarify how each domain contributes to Erbin’s physiological functions. Through 
the structural comparison of Erbin’s PDZ and the first PDZ of ZO-1 it was revealed that 
the less promiscuous PDZ of Erbin is likely responsible for its more specific protein 
interactions and strict localization to the adherens junction [81]. Structural studies have 
found that Erbin contains a class I PDZ domain, but surprisingly it interacts with ErbB2 
receptor tyrosine kinase which contains a class II type PDZ ligand. In order to understand 
how this unique interaction occurs, the Erbin PDZ domain was crystalized bound to a 
peptide containing the sequence found in ErbB2 ligand. The resulting structure showed 
that Erbin has a class I PDZ domain that only contains a single alpha-helix (compared to 
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the two alpha-helices typically present), and also confirmed that phosphorylation of ErbB2 
can alter its affinity of binding the PDZ domain of Erbin [82]. Another study confirmed 
these results using NMR to resolve the structure of the Erbin PDZ domain bound to its 
ligand. Erbin has a unique binding pocket due to the sidechains responsible for ligand 
binding and this helps to give the protein its specificity for binding PDZ ligands [75]. 
Additionally it was noted that like other PDZ ligand containing proteins, Erbin may form 
oligomers through PDZ-PDZ domain interactions [57]. 
In addition to studies on the PDZ domain there have also been studies investigating 
the role of the LRR domain plays in the localization of Erbin. Through the use of truncation 
and point mutations, it was shown that both the latter part of the LRR domain as well as 
two cysteine residues (amino acids 14 and 16), which can be palmitoylated, are necessary 
for the plasma membrane localization of Erbin [83]. However, different groups have 
separately shown that under certain conditions all of the domains in Erbin can potentially 
facilitate trafficking of Erbin to the plasma membrane. Different in vitro cell systems used 
in these studies may help explain the observed differences [81, 83, 84]. 
Since the initial characterization of Erbin, other interacting proteins in addition to 
ErbB2 have been identified. Several of these proteins are important for maintaining 
structural integrity of cell-cell junctions, including the interaction with bullous pemphigoid 
antigen 1 (eBPAG1) which is located at the hemidesmosome in keratinocytes [85]. 
Additionally at the hemidesmosome, Erbin interacts with the cytoplasmic tail of the β4 
integrin. The cytoplasmic tail of the β4 integrin can be phosphorylated, alters intracellular 
signaling associated with filopodia and lamellae formation in cancer, and has been 
implicated in increasing invasiveness of colon carcinoma cell lines [86, 87]. However, the 
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functional implication of the Erbin-β4 integrin interaction has not been investigated. It is 
interesting to hypothesize that Erbin could simultaneously control the activation of 
ErbB2/integrin signaling and facilitate structural protein interactions at the cell-cell 
junction [85].  
Other previous studies identified Erbin binding partners through the use of phage 
display. Several Erbin interacting proteins found are known to localize to the cell-junction 
[88]. These include three p120-like catenin proteins which bind the PDZ domain of Erbin. 
Interestingly the C-terminal ligands for two of the three proteins, ARVCF and δ-catenin, 
match the phage display for the perfect Erbin PDZ binding peptide even more so than that 
of ErbB2 [84]. Other studies were performed to confirm the interaction between Erbin and 
the third p120 catenin protein identified p0071, also known as plakophilin-4. p0071 is 
located at the desmosomes of epithelial cells where it connects the desmosome to the 
cellular cytoskeleton [89]. Lastly, Erbin was observed to co-localize with β-catenin along 
the lateral plasma membrane domain and E-cadherin junction [89, 90]. Further confirming 
this data, Erbin was found to be very abundant (10th most prevalent) at this site of E-
cadherin junctions in a gastric cancer cell line [91]. Taken together, in addition to its role 
in localizing ErbB2 receptors, these data implicate a role of Erbin in facilitating or at least 
an involvement in several protein-protein interactions that maintain epithelial cell 
junctions. As a LAP protein this may imply that Erbin may function similarly as LET-413 
or Scribble in maintaining epithelial cell structure.  
The functional role of Erbin on regulating RAS/RAF signaling was first described 
in a paper published in 2002 in that Erbin was shown to associate with active RAS, disrupt 
the RAS/RAF complex, and decrease downstream ERK signaling [92]. This was an 
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important discovery as it indicated that Erbin may have a direct interaction with signal 
molecules in addition to its role in restricting protein localization. Furthermore, in a 2006 
paper from the same group, Erbin was found to directly inhibit RAS/RAF signaling by 
replacing Shoc2, a scaffold protein that acts as a positive regulator of the RAS/RAF 
interaction [93], from the RAS/RAF complex.  
More recent studies have since begun to make connections between Erbin’s 
localization, interactions with structural proteins at cell-cell junctions, and ability to control 
signaling at those sites as well. One example of this was accomplished through studies of 
desmoglein-1 (DSG1), a desmosomal cadherin protein. Loss of DSG1 expression is linked 
to several diseases including RASopathies like striate palmoplantar keratoderma (SPPK) 
where keratinocytes fail to differentiate correctly, and additionally correlates to an 
increased risk for anal carcinoma [94]. Erbin has been identified as a potential interacting 
partner that is necessary for DSG1 induced ERK inhibition, which is necessary for 
controlling epithelial cell differentiation [95]. Mechanistically, over-expression of DSG-1 
increases the efficiency of Erbin binding to Shoc2. The increased Erbin/Shoc2 interaction 
effectively reduces downstream ERK signaling. In keratinocytes, Erbin suppression of 
MAPK signaling is necessary for correct cell differentiation and patients with SPPK have 
decreased Erbin-Shoc2 co-localization and increased RAS-Shoc2 co-localization which 
can possibly explain the RASopathy type of defects observed with this disease [95].  
Other studies have explored the physiological functions of Erbin in modulating 
MAPK signaling in neuronal cells. Several of these studies were performed in Schwann 
cells, the cells that produce a myelin sheath around neuronal axons helping to insulate 
peripheral nerves [96]. Loss of Erbin significantly reduced myelination of axons and once 
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again, the mechanism was linked to an increase in ERK signaling. In addition to the 
increased ERK signaling, the authors also noted decreased amounts of beta-catenin bound 
to E-cadherin, which potentially activates Wnt signaling. This could be rescued by 
treatment with U0126, a MEK inhibitor, suggesting that the increased ERK signaling 
resulting from loss of Erbin could be linked to increases in Wnt signaling [96]. 
In addition to Schwann cells, several other studies have elucidated additional roles 
for Erbin in neurons. Interestingly, Erbin was found to regulate neuronal development and 
Erbin knockout (KO) mice have impairment of motor coordination [97]. Erbin was found 
to affect AMPA receptor expression and stability on the surface of excitatory synapses 
[97], which could be a result of MAPK signaling that results from Neuregulin induced 
ErbB2 activation. Neuregulin activates ErbB receptors that are located at the postjunctional 
membranes of synapses. It has been shown that Erbin is necessary for the localization of 
ErbB2 to the surface of these postjunctional membranes [98], and Erbin stabilizes ErbB2 
protein levels in neural cells [99]. Additionally, Erbin null mice could not maintain 
appropriate levels of ErbB2 necessary for remylenation of axons after injury [100], and 
loss of Erbin decreased myelination which resulted in decreased nerve conduction velocity 
[99]. Together, the results obtained from studies of Erbin in neuronal cells suggest that 
Erbin can stabilize proteins localized at synapses and loss of Erbin leads to pathological 
alterations as a result of disruption of ErbB2 and MAPK pathways. 
More recently, studies began to explore and expand the role of Erbin outside of 
cell-cell junctions and MAPK associated signaling. An interaction with Smad proteins and 
a role in TGFβ signaling was discovered through more studies of Erbin in neural cells. 
Smad2 and 3 both interact with Erbin and not with other LAP proteins, Lano or Scribble 
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[101]. This was confirmed through a yeast two-hybrid screen, designed to detect proteins 
binding Smad3 in developing mouse orofacial tissue. Erbin was found to bind to the MH2 
domain of Smad3, and to a lesser degree Smad2 [102]. Regions of Erbin, from the linker 
region, comprised of amino acids from 1004-1280 or 1172-1282, since named the Smad 
Interacting Domain (SID), were found to be involved in binding Smad proteins. 
Additionally, through the use of point mutations, located outside of the binding pocket of 
Erbin’s PDZ domain, it was suggested that a slight electrostatic interaction with the exterior 
of the PDZ domain may also be involved in the binding to Smad3. Binding of Erbin with 
Smad3 inhibits Smad3/4 interactions from occurring by acting as a sink for Smad3 and 
reducing Smad induced signaling [101-103]. 
Within the same pathway it was also found that Erbin interacts with the SMAD 
anchor for receptor activation (SARA) to regulate TGFβ signaling. SARA binds non-
phosphorylated Smad2 and/or Smad3 and recruits them to active receptors where the 
Smads become activated through phosphorylation. SARA is localized to the plasma 
membrane and to early endosomes, where it was found to interact with Erbin. The SID of 
Erbin seems to have affinity for both Smad2/3 and SARA, in which SARA competes with 
Smads for binding Erbin and interaction of SARA with Erbin blocks Erbin-mediated 
inhibitory effects on Smad signaling [104]. Disruption of the interaction between Erbin and 
Smad has been observed in Atopy patients, a disease related to increased allergic reactions 
or immune responses. Mutations that occur in Erbin impair the formation of the Stat3-
Erbin-Smad2/3 complex, which alters the activation of T helper type 2 cytokine expression 
and results in elevated IgE in the patients with this disease [105].  
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Furthermore, studies using other biological systems have found that Erbin inhibits 
ERK signaling in heart tissues and loss of Erbin results in cardiac hypertrophy. In the Erbin 
KO mouse model, loss of Erbin exacerbated heart failure [106]. Additionally, it has been 
shown that Erbin interacts with nucleotide-binding oligomerization domain containing 
protein (Nod2) through the LRR domain in regulating inflammatory responses [107]. 
Improper activation of the Nod2 leads to Crohn’s disease and Blau syndrome, which affect 
intestinal and skin epithelial cells, respectively. Erbin inhibits the activation of NFκB and 
cytokine secretion induced by Nod2, and Erbin KO mouse embryos showed increased 
sensitivity to muramyl dipeptide, a component of bacterial cell wall. Interestingly, Erbin 
expression is strongly induced by inflammatory stimuli including LPS and TNFα. 
Collectively, these data suggest Erbin functions as a regulator of inflammation in epithelial 
tissues [108]. 
Taken together, these published studies use a variety of systems to explore the 
structure and function of Erbin. The studies on Erbin have evolved over time, from the 
initial characterization of Erbin as an ErbB2 binding protein to a protein that is involved in 
the formation and stability of epithelial cell junctions, and lastly as a protein that can 
modulate signaling through the RAS/RAF pathway. More recent studies have begun to 
focus on how Erbin-loss may be implicated in signaling events responsible for several 
disease states. Additionally, during the past decade a number of publications have begun 
to examine the role of Erbin in cancer. The functions of Erbin in maintaining epithelial 
integrity and serving as a negative regulator of oncogenic signaling were of particular 
interest in these studies.    
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1.4 The Role of Erbin in Cancer 
Although several of the Erbin-interacting proteins are well documented to be 
involved in oncogenic signaling, there are still relatively few publications investigating 
Erbin’s role in tumor initiation and/or progression.  Here, a comprehensive review of the 
existing publications on the functional role of Erbin in cancer are detailed. Previously 
published studies, prior to the start of this dissertation research project, were helpful in 
providing rationales for the dissertation study which focuses on elucidating the role of 
Erbin in regulating tumorigenesis and CRC progression and the underlying molecular 
mechanisms.   
Many of the first cancer related studies involving Erbin were related to the signaling 
processes which were more thoroughly explored in neuronal cells. One of the studies 
investigated Erbin-mediated regulation of Stat3 signaling in cervical cancer. Stat3 
signaling in cervical cancer had previously been correlated with a poor prognosis due to 
increased lymph node metastasis and tumor size, and increased expression and 
phosphorylation of Stat3 in cancerous and pre-cancer cervical lesions. It was found that in 
cervical cancer, Erbin regulates Stat3 and TGFβ signaling [105], and that loss of Erbin 
increases both the phosphorylation and nuclear translocation of Stat3, leading to 
transcriptional activation of target genes and tumor progression [109].  
Subsequently, from the same group, it was shown that Erbin loss allows cervical 
cancer cells to resist anoikis. Specifically, the authors found that loss of Erbin significantly 
increased cellular ATP levels and accelerated G1 to S cell cycle progression. The proposed 
mechanism is through the reduction of cell cycle inhibitors, p27 and p21, after loss of Erbin. 
Rescue experiments were performed to show that re-expression of p27 or p21 blocked 
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Erbin-loss induced increase in proliferation [110]. This study provides the initial evidence 
supporting a tumor suppressor role of Erbin in cervical cancer. Additionally, another study 
showed that expression levels of Erbin were controlled by the transcription factor c-Myb 
in a cell cycle dependent manner. The authors also noted that Erbin expression peaked in 
the G2/M phase and loss of Erbin resulted in the formation of multipolar spindles and 
ultimately abnormal chromosome division [74]. Together, these data suggest that loss of 
Erbin would result in both increased proliferation and chromosomal instability, which are 
both important factors in oncogenic progression.   
One of the most important areas of research regarding Erbin’s role in cancer is in 
breast cancer since one of the primary roles of Erbin is to restrict the localization of the 
ErbB2 receptor. This cancer type is of particular interest because ErbB2-overexpressing 
breast cancer represents 25-30% of invasive breast cancers. Two studies have focused on 
this particular type of cancer, but interestingly the two studies resulted in complete opposite 
findings [111, 112]. The first study suggested that Erbin is a tumor suppressor as Erbin 
levels were decreased in invasive breast carcinomas. This loss of Erbin coincided with 
increased phosphorylation of ERK as well as increased Akt phosphorylation. In addition, 
the authors also showed that knockdown of Erbin increased cell migration. Using the 
MEK1/2 inhibitor, PD184352, the authors were only able to partially reduce the cell 
migration observed in Erbin knockdown cells suggesting that the increase in migration 
results from an increase in signaling via both ERK and Akt pathways [111]. Furthermore, 
the paper suggested that Erbin-loss confers resistance to trastuzumab, a clinically used 
antibody targeting the ErbB2 receptor [113, 114]. Interestingly, the use of the Akt inhibitor 
GDC0941, but not the MEK inhibitor, was able restore trastuzumab sensitivity in MCF-7 
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cells stably overexpressing ErbB2 in Erbin knockdown cells [111]. 
Conversely, using a murine model of ErbB2-driven breast cancer, a second study 
found that Erbin can act as a tumor promoter [112]. Particularly, knockout of the C-
terminal PDZ domain of Erbin in vivo decreased the expression of ErbB2 at the protein 
level but had no effect on ErbB2 mRNA expression. Mechanistically, the presence of Erbin 
blocked ubiquitination of ErbB2 by enhancing ErbB2/HSP90 interactions. This increased 
ErbB2 protein stability led to activation of oncogenic signaling downstream of ErbB2 in 
Erbin mutant mice [112]. Nevertheless, this tumor-promoting effect is likely specific to 
cancers driven by ErbB2, since deletion of the C-terminal PDZ domain of Erbin had no 
effect on tumorigenesis in the MMTV-PyVT driven breast cancer model. While these 
interactions and mechanism of tumor promotion may be unique to this type of breast 
cancer, recently a review article was published proposing peptide inhibitors of the 
Erbin/ErbB2 interaction so that HSP90-mediated stabilizing ErbB2 can be disrupted in 
treating ErbB2-driven breast cancer [115]. However, it remains to be seen whether a mouse 
model lacking Erbin entirely, not just the PDZ domain of Erbin, would have a tumor 
inhibitory or promoting effect in an ErbB2 driven tumor model. While truncation of the 
PDZ domain of Erbin may abolish any direct Erbin-ErbB2 receptor interaction, the N-
terminus and LRR of Erbin have also been shown to result in Erbin plasma membrane 
localization. This plasma membrane localization could result in the truncated Erbin 
maintaining certain protein interactions, possibly altering ErbB2 signaling indirectly. More 
studies will be necessary to better understand the complexity of how Erbin alters ErbB2 
signaling in different cancer types.  
In studies determining the role of Erbin in regulating Wnt signaling, it has been 
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shown that Erbin can interact with β-catenin in HEK293 cells using immunoprecipitation 
experiments. The functional effect of this interaction was investigated using a fluorescent 
reporter system, the TOPflash luciferase reporter plasmid, to measure Wnt signaling 
activation in the HEK293 and CRC HCT116 cells. Overexpression of Erbin inhibited 
activation of Wnt target in the reporter assay [116]. While the experiments in this brief 
publication began to explore the role of Erbin in inhibiting Wnt signaling, there were no 
experiments performed to explore the physiological consequences of this inhibition.  
Furthermore, another study utilized multicellular tumor spheroid models to 
investigate the role Erbin in the formation of CRC tumor spheroids in suspension. Given 
the fact that many of Erbin-interaction proteins are at the site of cell-cell junctions, it has 
been suggested that Erbin could be necessary for maintaining the interactions of junctional 
proteins in epithelial cells. This study explored the possibility of certain proteins, including 
LAP proteins such as Erbin, being required for the growth of tumor spheroids using HT29 
CRC cells [117]. The cells were grown as traditional 2D monolayer or in suspension for 
three days. The tumor spheroids were collected from the suspension medium and protein 
and mRNA levels were compared to the cells grown in 2D. Erbin was one of the most 
highly upregulated proteins observed in tumor spheroids. Knockdown of Erbin with siRNA 
dramatically decreased the ability of cells to grow in suspension [117]. Results from this 
study suggest that loss of Erbin prevents cells from forming the cell-cell junctions required 
to form multicellular spheroids, and therefore resulted in anoikis. More recently, results 
from one study suggested that Erbin functions as a tumor promoter in CRC cells by 
facilitating the interaction between EGFR and ErbB2 receptor with the E3 ligase C-Cbl 
[118].  
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In summary, the literature on Erbin-mediated regulation of cell signaling suggests 
that Erbin negatively controls several pro-growth signaling pathways; including the 
RAS/RAF, Akt, Smad, and possibly the Wnt pathway. However, the role of Erbin in 
regulating cell polarity, especially in the context of EMT and CRC progression has not 
been studied and the role of Erbin in regulating CRC invasion and metastasis remains 
controversial [118, 119]. My dissertation studies focused on testing the hypothesis that 
Erbin act as a tumor suppressor in CRC.   
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1.5 Goals and Hypothesis for Dissertation 
The proper establishment of epithelial polarity allows cells to sense and to respond 
to signals that arise from the microenvironment in a spatiotemporally controlled manner. 
Therefore, regulation of cell-cell junctions, maintaining cell polarity, and properly 
controlling cell signaling are vital for halting cancer initiation and progression. Previous 
studies have demonstrated that loss of cell-polarity, through the disruption of these 
junctions, is associated with late stage metastatic tumors where cancer cells undergo EMT 
[120-122]. The function of several well-known oncogenic proteins and tumor suppressors, 
such as ErbB2, Kras, and Lkb1, were observed to regulate both cell signaling and the 
integrity of epithelial polarity [121, 123-126]. 
Given that many other proteins in the LAP family have also been associated with 
maintenance of epithelial polarity and controlling oncogenic signaling, and after a 
comprehensive review of the literature it was obvious that a more rigorous study on Erbin’s 
role in these processes in CRC was needed. As previously noted, the development of CRC 
involves the activation of oncogenic signaling through the Wnt, PI3K/Akt and RAS/RAF 
pathways in epithelial cells, all of which Erbin has been implicated in regulating and thus 
makes CRC an ideal disease model to characterize the function of Erbin. Therefore, the 
primary goal of my dissertation work is to understand the role of Erbin in suppressing the 
initiation and progression of CRC, with a focus on elucidating the molecular mechanisms 
by which Erbin regulates epithelial cell polarity and EMT during cancer progression. By 
employing Erbin knockout mouse models, the functional importance of Erbin was 
investigated in vivo. Together, a combination of in vitro and in vivo studies as well as CRC 
patient data were used to better understand how Erbin-loss promotes CRC progression. The 
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overall goal of my thesis work has been accomplished as a result of the steps detailed in 
the following Results and Discussion chapters: 
1) Characterize the expression of Erbin in CRC patient tumor samples. 
2) Determine the effect of Erbin-loss in regulating cell signaling and the 
underlying molecular mechanism.  
3) Define the functional consequences of Erbin-loss in CRC cells.  
 4) Examine the role of Erbin in tumorigenesis in vivo through the use of the 
Apc/Erbin KO compound mutant mouse model.  
 5) Determine other possible mechanisms of action that allow Erbin to act as a 
tumor suppressor in CRC.   
  35 
CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell Lines and Cell Culturing 
Caco2 and SW480 cells obtained from American Type Culture Collection (Manassas, VA) 
were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS, Sigma-Aldrich) and 1% penicillin/streptomycin. LIM2405 
obtained from Ludwig Cancer Research Institute were cultured in RPMI-1640 
supplemented with 10% FBS, 2mM L-Glutamine, 25mM HEPES and 1% 
penicillin/streptomycin. Stable Erbin and KSR1 knockdown cells were generated by 
lentivirus-based shRNAs as previously described. [37, 127, 128]. The shRNA targeting 
sequences for Erbin are as the following: 5’-GCAGCCAAGTACAACCGTTAA-3’ (A1) 
and 5’- CGGGCTCAAGTTGCATTTGAA-3’ (A2). The shRNA targeting sequence for 
KSR1 is 5’-CAACAAGGAGTGGAATGATTT-3’.  
To generate WT and Erbin knockout mouse embryonic fibroblast (MEF) cells, 
Erbin heterozygous mice were used for breeding and individual embryos at day 13 of 
gestation were isolated and genotyped. MEF cells were produced from WT and Erbin null 
embryos by following standard protocols [129]. The primary MEF cells were immortalized 
using retrovirus-mediated knockdown of p53 using pBabe-puro-shp53 (Addgene). 
The Erbin antibody has been reported previously [89]. The phospho-AKT (p-AKT 
for Ser473), pan-Akt, phospho-RAF1 (p-RAF1 for Ser338), total RAF1, phospho-MEK1/2 
(p-MEK for Ser217/221), total MEK1/2, phospho-ERK1/2 (p-ERK for Thr202/Tyr204), 
total ERK1/2, and E-cadherin antibodies were from Cell Signaling. The vimentin and N-
cadherin antibodies were from BD Biosciences. The β-actin and γ-tubulin antibodies were 
from Sigma-Aldrich.  
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2.2 Gene Knockdown by shRNA 
For stable knockdown of ERBIN or KSR1, lentivirus was produced by combining 
constructs for packaging (psPAX2), envelope (pDM2G) vectors and targeting shRNA or a 
non-targeting vector (pLKO.1), at a 4:2:1 ratio (vectors obtained from Sigma Aldrich, St. 
Louis, MO). Transfection reagent, polyethylenimine (PEI; Polysciences) was mixed with 
the DNA at 5:1 ratio, DNA to PEI. This was added to 50% confluent HEK 293LTV cells 
that had been passaged 24 hours prior to transfection. Conditioned, virus containing media 
was collected 48 and 72 hours after transfection, centrifuged at 2,000 x g for 5 mins and 
viral supernatant collected. Supernatant was then passed through a 45µm filter to ensure 
sterility. CRC cell lines were passaged to 50% confluence and viral supernatant, along with 
8 μg/ml hexadimethrine bromide (polybrene, Sigma Aldrich), were added to the cells. Viral 
supernatant was added again 24 hours later, and 48 hours later was replaced with normal 
growth media. Stable cell line selection was accomplished via puromycin (1-8 μg/ml 
depending on the cell line) for a minimum of one week.  Stable knockdown of the specified 
protein was observed by collection of cells after selection, followed by Western blot for 
the protein of interest.  
2.3 Cell Growth Assay 
 Cell lines were plated at a density of 20,000 cells per 12 well plate and allowed to 
grow for 72 hours. After allowing the cells to proliferate, media is aspirated and wells were 
washed once with PBS, and then cells were fixed with methanol (500μl) for 10 minutes.  
Following fixation the methanol is removed and cells are stained with 500μl of crystal 
violet solution (0.5% Crystal violet and 20% methanol) for 30 minutes. After 30 minutes 
the crystal violet is removed, the 12 well plate is gently rinsed with water until all excess 
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stain is removed, and then the plates are air dried. Cells and associated staining is then 
solubilized in 500μl of 1% SDS in water. The 12 well plate is placed on a shaker at room 
temperature until all of the stain is dissolved in solution and no cells are visible on the 
bottom of the plate. 100μl, in triplicate, is removed from each well of the 12 well plate and 
placed into a 96-well plate followed by reading the absorbance at 570nm (SpectraMR. 
Dynex Technologies). 
2.4 RNA Extraction and QPCR 
Total RNA was isolated from mouse tumor organoids using the RNeasy Mini Kit (Qiagen, 
MD, USA). Equal amounts of RNA were used as templates for the synthesis of cDNA 
using RT2 HT First Strand kit (Qiagen). Real-time PCR was performed using mouse Lgr5-
, Axin2- Cd44-, Ccnd1-, Ki67-, Alpi-, Fabp2- and Muc2-specific probes using StepOne 
Real-Time PCR system (Applied Biosysems). All values were normalized to the level of 
β-actin. The overall expression of β-actin mRNA remained unchanged in different 
treatment groups as determined by the Ct (threshold cycle) values. 
2.5 Transwell Migration and Invasion Assay  
Cell lines were grown to 50% confluency and were serum starved overnight. The 
next day, the cells were resuspended in 0.1% bovine serum albumin (BSA), then seeded 
into the upper chamber of Transwell inserts with an 8 µm pore size membrane (Corning, 
Tewksbury, MA) at 5x104 cells per insert. For the invasion assay, upper chambers of 
Transwell inserts were coated with 100µls of Matrigel (BD Biosciences), which was 
allowed to dry overnight and rehydrated prior to seeding of cells for invasion. The cells 
were allowed to migrate toward serum-free DMEM containing collagen (15 µg/mL) and 
Epidermal Growth Factor (EGF) (10 ng/mL) in the lower chamber for 4.5 hr (24 hours for 
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invasion). At the end of the incubation period, cells remaining in the top chamber were 
mechanically removed using a cotton swab, and the cells on the bottom of the Transwell 
inserts were fixed with methanol (10 min), washed once with phosphate buffered saline 
(PBS), and then stained with 0.5% (w/v) crystal violet in 20% methanol (v/v) (20 min). 
The stained cells in 4 non-overlapping fields from each insert were counted with an 
inverted microscope, using the 20X objective (Eclipse TS100, Nikon Instruments, 
Melville, NY). 
2.6 Drug Treatment  
Inhibition of signaling pathways using pharmacological inhibition was 
accomplished through the use of PD98059, a specific MEK1 inhibitor, and MK2206 a 
specific inhibitor of Akt. Cells for motility assays were starved and simultaneously 
incubated with the inhibitors, at 10μM and 1μM respectively, overnight prior to Transwell 
assay. Additionally, the inhibitors were also included in the chemoattractant containing 
medium for the duration of the assay.  
2.7 Single Cell Motility Assay 
 Control and Erbin knockdown cells were serum starved for 4 hours and plated as 
single cells onto collagen (15 µg/mL) coated glass bottom culture dishes (MatTek). Cells 
were stimulated with EGF (10 ng/ml) and the trajectory of moving cells were captured 
using a Nikon BioStation IM equipped with a CO2 incubation chamber. Time-lapse phase 
images were taken every 10 minutes for 6 hours with a 20X objective [37, 130].  The 
recorded movement of the cells was analyzed using Nikon Elements AR software.  
  39 
2.8 Western Blotting Analysis 
Cells were collected and pelleted for Western blot analysis by placing the 10cm 
culture dishes containing the cells on ice and rinsing once with cold PBS, followed by the 
addition of 1ml of cold PBS and scraping cells, transferring them to a 1.5ml centrifuge vial. 
Cells were quickly pelleted by centrifugation, 3000rcf for 30 seconds. Pellets were then 
lysed with 100-300 l cold PPHB lysis buffer (50 mM Na2HPO4, 1 mM Sodium 
Pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton®X-100) with the 
addition of DTT, benzamidine, leupeptin, PMSF, and sodium orthovanadate (0.5M, 0.5M, 
4mg/mL, 0.2mM, and 200µM respectively). Cells were vortexed and lysed for 5 min on 
ice followed by centrifugation, 18,000rcf for 3 minutes. Supernatant containing soluble 
proteins were placed in new tubes and protein levels were quantified via Bradford assay 
followed by normalization. Sample buffer (4X) was added at a ratio of 1:3 and proteins 
were then separated using 8% SDS-PAGE, transferred and immunoblotted.  
2.9 2-D Immunofluorescent Staining  
 Cells were grown at 37°C in DMEM on glass coverslips. They were washed twice 
with PBS and fixed with 4% paraformaldehyde in PBS for 20 min. All incubations were 
performed at 22°C. Fixed cells were washed thrice with PBS and then permeabilized with 
0.01% Triton®X-100 in PBS for 10 min. Cells were washed thrice with PBS and then 
incubated with labelling buffer (1% BSA in PBS, pH 7.4) for 30 min. Primary antibodies 
were diluted in the labelling buffer and incubated with the fixed cells for 1 hr. The cells 
were washed thrice with PBS and subsequently incubated for 1 hr with either Alexa 594-
conjugated anti-rabbit or Alexa 488-conjucated anti-mouse IgG (Invitrogen, Grand Island, 
NY) diluted in the labelling buffer. The coverslips were washed twice with PBS and once 
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with distilled water, then mounted on slides. The distributions of the immunodecorated 
proteins were visualized using an Olympus FlowView FV1000 confocal laser-scanning 
microscope (Olympus, Center Valley, PA). 
2.10 3-D Immunofluorescent Staining 
Caco2 cells were grown in a 3D matrix consisting of 50% growth-factor reduced 
Matrigel (BD Biosciences) and 50% Collagen I (Collagen I, Bovine, Invitrogen, cat.# 
A10644-01) neutralized with NaOH prior to mixing. Initially, the bottom of a 24 well plate 
is coated with 200 µl of the Matrigel-Collagen mixture and incubated at 37°C for 30 min. 
Caco2 cells from normal 2D cell culture are then trypsinized, re-suspended on ice in cell 
suspension medium (2% FBS and 2% Matrigel in DMEM) at a concentration of 2,500 
cells/ml. Then, 500 µl of the cell containing solution is added on top of solidified Matrigel-
Collagen mixture in the 24 well plate. Cell suspension medium was changed every 4-5 
days, and Caco2 cells were allowed to grow 11 days until acini were formed.  
After acinar structures were fully formed they were visualized using phase-contrast 
imaging. The imaging was done using a Nikon Eclipse Ti-E inverted microscope, and 
analyzed using the NIS-Elements AR 3.2 software (Nikon). The 3D matrix was partially 
dissociated by incubating with Collagenase I (30 m at 37°C) and cells were fixed using 4% 
paraformaldehyde in PBS (30 min at 4°C). All futher incubations were performed at 22°C. 
The fixed acini and Matrigel solution were pipetted into microcentrifuge tubes, spun down 
and washed thrice with PBS. Keeping the acini pellet in the microcentrifuge tubes, the cells 
were permeabilized with 0.01% Triton®X-100 in PBS for 20 min. Cells were spun down 
and washed thrice with PBS and then incubated with labelling buffer (1% BSA in PBS, pH 
7.4) for 1 h. Primary antibodies were diluted in the labelling buffer and incubated with the 
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fixed cells for 1 hr. The cells were spun down and washed thrice with PBS and 
subsequently incubated for 1 hr with either Alexa 594-conjugated anti-rabbit or Alexa 488-
conjucated anti-mouse IgG (Invitrogen) diluted in the labelling buffer. The acini were spun 
down and washed thrice with PBS, diluted in distilled water and transferred to a slide. To 
detect proliferating cells, the cells grown in 3D culture were treated with 5-ethynyl-2´-
deoxyuridine (EdU) for 1 h prior to fixation. The EdU positive cells were stained using 
Click-iT EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific). Images were taken 
using an Olympus FlowView FV1000 confocal laser-scanning microscope (Olympus). 
2.11 Histologic analysis and immunohistochemical (IHC) staining 
 Mice were euthanized at indicated time-points when showing signs of intestinal 
neoplasia, such as a hunched stature and rectal bleeding. Intestine segments were opened 
longitudinally onto filter paper and made into “Swiss-roll” preparations as described 
previously [37]. For histological analysis, H&E sections were prepared from fixed and 
paraffin embedded Swiss-roll specimens by following standard techniques. The CRC 
tissue microarray was created by the Biospecimen Procurement and Translational 
Pathology Shared Resource Facility of the Markey Cancer Center, which contains 45 pairs 
of tumor and adjacent normal control tissues collected from CRC patients who had 
undergone surgery resections at the Markey Cancer Center. For IHC staining, tissue 
sections were deparaffinized, rehydrated, and treated with hydrogen peroxide. Antigen 
retrieval was performed using Dako Target Retrieval Solution (DakoCytomation), and IHC 
staining was performed as previously described [127]. The stained sections were visualized 
using a Nikon Eclipse 80i upright microscope.  
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2.12 Mice 
All animal procedures were performed by following protocols approved by the University 
of Kentucky Institutional Animal Care and Use Committee. Erbin knockout mice on 
C57BL6 background as previously described [99] were maintained by random inter-
crossing to sustain a heterogeneous mixed genetic background. To produce animals used 
in the experiments, Erbin+/– mice were bred with Apcf/f and Villin-cre (Vil-cre) mice (both 
were obtained from the Jackson Laboratory) on a C57BL6 background. These mice were 
then inter-crossed to produce three cohorts of animals, including Apcf/+/Erbin+/+/Vil-cre 
(Apc/WT), Apcf/+/Erbin+/–/Vil-cre (Apc/Het), and Apcf/+/Erbin–/–/Vil-cre (Apc/KO). To 
monitor survival, these cohorts of mice were followed for up to 6 months.  
2.13 Isolation and culture of mouse organoids 
 Intestinal tumors were isolated from three cohorts of Apc/Erbin compound mutant 
mice, including Apc/WT, Apc/Het and Apc/KO, cultured in 3D Matrigel. Fresh mouse 
intestines, containing tumors, are opened longitudinally and multiple tumors are resected 
while trying to avoid the removal of adjacent and underlying normal tissues. Immediately 
following resection, the tumors were placed into ice-cold DMEM/F12 supplemented with 
antibiotics, and transported to the laboratory. Once in the laboratory, using sterile 
technique, the tumors are washed once with cold PBS and, using a sterile razor, are minced 
into 3mm3 chunks and transferred into a 15 ml sterile tube. The pieces of tumor are wash 
once more with cold PBS and then centrifuged at 200rcf for 3 minutes. After aspirating the 
PBS, in order to further break down the tumor pieces to individual cells, 5ml of dissociation 
buffer (DMEM/F12 + 2.5% FBS, penicillin/streptomycin, 75 U/mL collagenase type IV 
[Sigma], 125μg/mL dispase type II [Invitrogen] and DNAse) was added to the 15ml tube 
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and these are incubate for 45 minutes at 37°C with agitation. After the digestion step, the 
larger tissue fragments are allowed to settle down under normal gravity, and the 
supernatant is collected into a fresh 50ml Falcon tube, which should contain the single 
tumor cells. Centrifuge the 50ml tube in order isolated tumor cells at 200rcf for 3 minutes.  
Wash once with 5ml of PBS and resuspend the cells in 20ml PBS in order to pass through 
a 70μm cell strainer to once again remove any larger cellular debris. Centrifuge the filtrate 
at 200rcf for 3 minutes, aspirate PBS, and wash the cells with 5 ml DMEM/F12 medium 
containing 10% FBS, penicillin and streptomycin in order to remove any remaining 
digestion buffer. Once again, spin down at 200rcf for 3 minutes, aspirate the wash medium 
and resuspend the cells in 100μl of 33% Martrigel on ice. Add this tumor cell-Matrigel 
mixture to a 24-well plate pre-coated with 200μl of solidified, 33% Matrigel. Place this 
plate in the 37°C incubator to allow the Matrigel to solidify around the cells and then add 
500μl of Basal Medium (Advanced DMEM/F12 medium supplemented with 
penicillin/streptomycin, 1X Glutamax, 1X N-2, 1X B-27, and 1mM N-Acetyl-L-cysteine). 
Change medium every 2-4 days as needed. Tumor organoids were allowed to grow for 5 
days and collected for protein or RNA analysis. For colony formation assays, single cell 
suspensions of 1,000 cells derived from tumor organoids were seeded into 3D Matrigel as 
described above. The number of colonies formed after 5 days were counted using an 
inverted microscope.  
 Conversely, in order to grow organoids from normal, non-tumorigenic intestinal 
tissue, a piece of intestine was taken from WT, Erbin Het, and Erbin KO mice. In order to 
isolate the tissue, fresh mouse intestine was opened longitudinally and chopped into small 
pieces (3-5 mm2) and the intestines were washed with cold PBS until the supernatant was 
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clear. Ten milliliters of cold digestion buffer (2 mM EDTA, 0.5 mM DTT in PBS) was 
added and incubated on ice for 30 minutes, then mixed briefly a few times during this 
process, to start cellular dissociation. To further dissociate the crypts from the normal 
intestines, the digestion buffer was aspirated followed by the addition of 5 ml of TrypLE 
Express and digestion at 37°C for 15 minutes. Again, after this time period we allowed the 
tissue pieces to sediment, and aspirated TrypLE Express, followed by adding cold PBS and 
vortexing vigorously to dislodge crypts. Individual villi and crypts dissociated from the 
underlying intestinal wall stroma, and should be suspended in the supernatant. The 
supernatant was collected and passed through a 70μm strainer to remove the larger villous 
materials. The supernatant was centrifuged to spin down and pellet the crypts at 200rcf for 
3 minutes. Finally, in order to remove any remaining digestion buffers we washed the 
crypts with 5 ml DMEM/F12 medium containing 10% FBS, penicillin and streptomycin, 
followed by another centrifugation step at 200rcf for 3min. The medium was aspirated and 
the crypts were resuspended in 100μl of 33% Matrigel, then we added this crypt-Matrigel 
mixture to a 24-well plate pre-coated with 200μl of solidified, 50% Matrigel. After the 
crypts were plated, they were placed in the 37°C incubator to allow the Matrigel to solidify 
around the crypts. Lastly, to prevent the Matrigel from dehydrating, 500μl of 
Intestine/Colon Organoid Medium (Advanced DMEM/F12 medium supplemented with 
penicillin/streptomycin, 1X Glutamax, 1X N-2, 1X B-27, and 1mM N-Acetyl-L-cysteine, 
supplemented with 100 ng/ml Noggin, 50 ng/ml EGF, and 1 μg/ml R-spondin-1) was added 
on top of the Matrigel. The media was changed every 2 days of culture.  
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2.14 Bioinformatic and statistical analysis 
 In experiments to assess gene or protein expression, rate of cell migration, size and 
number of cell grown in 3D, and EdU incorporation were summarized using bar graphs 
and pairwise comparisons between different conditions were carried out using two-sample 
t-tests. We collaborated with the Markey Cancer Center – Biostatistics and Bioinformatics 
Shared Resource Facility to determine the relative expression of Erbin gene in human CRC 
patients. This was accomplished by downloading microarray and patient clinical data from 
two CRC studies from the Oncomine database. The Cancer Genome Atlas (TCGA) dataset 
contains 192 adenocarcinoma and 22 normal samples, within which 13 were matched pairs. 
Expression of Erbin was examined using linear mixed models. The Skrzypczak et al. 
dataset contains 81 tumors and 24 normal samples. Here, the expression of Erbin was 
examined using a 2-sample t test.  
For the Gene Set Enrichment Analysis (GSEA), RNA sequencing data with over 
60,000 genes were obtained from the TCGA Colorectal Cancer study. Once again working 
with the Biostatistics and Bioinformatics Shared Resource Facility, the corresponding gene 
expression data between ERBIN and the other genes was analyzed to obtain a Spearman 
correlation value. The genes were then ordered from highest to lowest based on the 
correlation values. This ranked list was used for the GSEA analysis [131].   
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CHAPTER 3: RESULTS 
3.1 Introduction 
Erbin is a member of the leucine-rich repeat (LRR) and PDZ domain (LAP) protein 
superfamily. It contains multiple protein-protein interaction modules including 16 LRRs 
followed by a single PDZ domain at the C-terminus. Erbin is known to localize primarily 
to the adherens junction and plays a role in maintaining the structural integrity of the 
junction in epithelial cells [85, 88, 89]. The initial discovery of Erbin identified Erbin as 
an ErbB2/Her2 receptor interacting protein that facilitates the localization of the receptor 
to the basolateral membrane of epithelial cells [73]. In addition, it has been shown that 
Erbin attenuates RAF1 activation by disrupting Shoc2-mediated RAS/RAF interaction [92, 
93]. Moreover, downregulation of Erbin results in resistance to anoikis in cervical cancer 
cells via activation of JAK/STAT signaling [109]. However, the role of Erbin in regulating 
cell polarity, especially in the context of EMT and colorectal cancer (CRC) progression, 
remains elusive.  
It has been well documented that epithelial cells, including those in the 
gastrointestinal tract, become polarized during the differentiation process [132]. The 
polarization process, characterized by the formation of specialized junctions between 
neighboring cells, also results in the segregation of two plasma membrane domains: the 
apical surface, facing the external medium, and the basolateral surface, connected to 
adjacent cells and extracellular matrix [133, 134]. The apical and basolateral membranes 
are segregated by two highly organized junctions, tight junctions and adherens junctions; 
and the many proteins that compose these junctions are assembled at the site of cell-cell 
contact [135-137]. Previous studies have demonstrated that loss of cell polarity, through 
the disruption of these junctions, is associated with late stage metastatic tumors where 
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cancer cells undergo EMT [120-122]. Therefore, the proper establishment of epithelial 
polarity allows cells to sense and respond to signals that arise from the microenvironment 
in a spatiotemporally controlled manner. 
By facilitating the assembly of tightly controlled signaling complexes through 
protein-protein interactions, scaffold proteins are known to play important roles in 
regulating spatiotemporal responses in cell signaling [56]. One of the best-known examples 
is the signal propagation in the RAS/RAF pathway, where the step-by-step activation 
process from RAS to ERK is facilitated by scaffolding proteins [138, 139]. KSR1, a kinase-
like protein that lacks enzymatic activity, has been shown to promote cell proliferation and 
oncogenic potential by enhancing signaling activation through the RAS/RAF pathway 
[140]. KSR1 binds constitutively to MEK in the cytoplasm in unstimulated cells and 
translocates to the plasma membrane upon RAS activation [141, 142]. At the plasma 
membrane, KSR1 facilitates signaling propagation by organizing the formation of 
RAF/MEK/ERK complex [142, 143]. Although the molecular mechanism by which 
scaffold proteins positively regulate RAS/RAF signaling has been extensively studied, it 
remains largely unknown whether scaffolding proteins are involved in signaling 
termination.  
Here, we report the identification of Erbin as a novel tumor suppressor in colon 
cancer. We show that the mRNA and protein expression of Erbin is markedly decreased in 
CRC patient specimens. Erbin negatively regulates RAS/RAF signaling by sequestering 
KSR1 and preventing the formation of KSR1/RAF1 complex. Functionally, knockdown of 
Erbin results in an increase in cell motility by inducing EMT in colon cancer cells, and 
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deletion of Erbin gene significantly decreases the lifespan of Apc mutant mice and 
accelerates the tumor progression.  
3.2 Erbin’s role as a scaffold protein –  
3.2.1 Erbin mRNA expression is significantly downregulated in CRC patient tumor tissue 
To determine if Erbin could potentially serve as a tumor suppressor in CRC, we 
began by examining Erbin mRNA expression (gene symbol: ERBIN; previously known as 
ERBB2IP) in CRC patients. We performed bioinformatic analysis of two microarray data 
sets of human CRC samples. The microarray and patient clinical data of the two studies 
[24, 25] were downloaded from the Oncomine database. We collaborated with Dr. Chi 
Wang at the Biostatistics and Bioinformatics Shared Resource Facility of Markey Cancer 
Center to determine the relative expression of Erbin gene in human CRC patients. The 
Cancer Genome Atlas (TCGA) dataset contains 192 adenocarcinoma and 22 normal 
samples, within which 13 were matched pairs. Expression of Erbin was significantly higher 
in normal samples than in tumors (P<0.001 based on linear mixed models). The Skrzypczak 
et al. dataset contains 81 tumors and 24 normal samples. Here, the expression of Erbin was 
also significantly higher in normal samples than in the tumors (P<0.001 based upon a 2-
sample t test). The mRNA expression levels of Erbin, in both tumor samples and normal 
tissue samples can be seen in Figure 3.1 A-B.  
 Further analysis was also performed using the microarray and patient clinical data 
from the TCGA data set [144]. These patient samples were further divided into groups of 
normal tissue as well as the adenocarcinoma samples were separated into cancer stages (I-
IV). Erbin mRNA levels decreased upon tumor initiation as seen by the decrease in Erbin 
mRNA in stage 1 tumor tissue when compared to normal tissue (Figure 3.2). However, 
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while a decrease is observed in stage 1, no further loss of Erbin mRNA is observed as the 
tumor progresses through stage 2-4.  
3.2.2 Erbin is mislocalized in patient tumor tissues as determined by IHC 
In addition to examining the mRNA levels, we determined the expression of Erbin 
protein in matched normal and colon cancer tissues by IHC staining. We obtain a Tissue 
Microarray (TMA) from the Biospecimen Procurement and Translational Pathology 
Shared Resource Facility of Markey Cancer Center, which contains 45 normal tissue 
samples and 45 tumor tissue samples. After IHC staining for Erbin, we noticed the 
expression of Erbin was along the epithelial cell-cell junction in normal human colon 
tissues whereas Erbin expression was markedly reduced and mislocalized to cytoplasm in 
tumor tissues (Figure 3.3 A). The basolateral distribution of Erbin in normal tissues was 
found to be consistent with those observed previously [3, 26]. In order to quantify these 
results, the basolateral localization of Erbin was determined for each tissue section on the 
TMA (scoring was blinded as to remove any bias), and the percentage of samples positive 
for basolateral membrane localization was graphed. Basolateral membrane localization of 
Erbin was lost in all CRC tumor tissues examined (Figure 3.3 B and C).  
3.2.3 Erbin protein levels are significantly decreased in CRC patient tumor tissue 
Furthermore, in addition to looking at Erbin protein localization, we analyzed Erbin 
protein expression in matched normal and tumor tissues obtained from seven CRC patients 
using Western blot (Figure 3.4 A). While the calculated molecular weight of Erbin is 
approximately 150 kDa, Erbin expression was detected as a doublet around 180 kDa on 
our Western blots. This has been observed previously and reported by several other groups 
[73, 85]. Consistent with IHC staining results, Erbin protein levels were significantly 
decreased in tumor tissues compared to normal controls (Figure 3.4 B). These tissues were 
  50 
collected from seven patients that were at various stages of tumor progression, from T2 to 
T4a (Figure 3.4 C). The decrease in Erbin protein corresponds with the mRNA data shown 
in Figure 3.2, suggesting that Erbin expression is decreased upon tumor initiation and is 
not dependent on tumor stage. Collectively, these data obtained using patient samples 
provide the first evidence that Erbin may function as tumor suppressor in CRC.  
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Figure 3.1 Erbin is downregulated in CRC patient samples 
(A) and (B), Microarray and patient clinical data from two colorectal cancer studies were 
downloaded from the Oncomine database. Data from Skrzypczak et al [145](A) 
contained 24 normal and 36 adenocarcinoma samples; data from TCGA [144] (B) 
contained 22 normal and 192 adenocarcinoma samples. Two-sample t-tests or linear 
mixed models were used to compare ERBIN gene expression between adenocarcinoma 
and normal samples (p < 0.001).  
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Figure 3.2 Erbin mRNA is downregulated in stage I colorectal cancer 
Microarray and patient clinical data from TCGA [144] which contains normal and 
adenocarcinoma samples were separated into cancer stages (I-IV). Consistent with Figure 
3.1, Erbin mRNA levels are decreased in tumor tissue when compared to normal tissue. 
However, a notable loss of Erbin mRNA occurs in stage I and remain low throughout 
CRC progression.  
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Figure 3.3 Erbin is mislocalized in CRC patient tumor tissue 
(A) The expression of Erbin protein was detected in a tissue microarray (TMA) using 
IHC. The TMA contains 45 pairs of matched normal and tumor tissues. The basolateral 
localization of Erbin was detected in normal colonic epithelial cells as indicated by red 
arrows. (B) Bar graph depicts the percentage of basolateral localization of Erbin in both 
normal and tumor tissues (n=45). (C) Representative images of IHC staining for Erbin in 
CRC TMA. Erbin was localized to the basolateral membranes in normal tissues and 
diffuse in tumor tissues. Scale bar, 100μm.  
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Figure 3.4 Erbin protein expression is decreased in CRC patient tumor tissue 
(A) Matched normal and tumor tissues from seven CRC patients were analyzed for Erbin 
expression using Western blot and Erbin antibody [89] (B) The expression of Erbin protein 
was quantified by normalizing to tubulin or actin. The relative Erbin levels in tumor tissues 
were compared to Erbin levels in the normal tissues from the same patient. Data represents 
the mean  SEM (# p<0.0001). (C) De-identified patient data associated with tissues used 
for detecting Erbin protein expression by Western blot.   
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3.2.4 Erbin knockdown in CRC cells alters cell signaling 
Previous studies have suggested that Erbin negatively regulates ERK signaling [5, 
27]. To determine the function of Erbin in CRC, we silenced Erbin expression using two 
shRNA lentiviral targeting constructs (A1 and A2) in SW480, LIM2405 and Caco2 colon 
cancer cell lines. Consistently, knockdown of Erbin resulted in an increase in 
phosphorylation and activation of both the Akt and MEK/ERK pathways in all three cell 
lines (Figure 3.5 A). Since both Erbin shRNA targeting constructs had similar effects on 
silencing Erbin expression and enhancing activation of Akt and MEK/ERK 
phosphorylation, the subsequent experiments were mostly performed using sh-Erbin-A2 
shRNA and key findings were confirmed with sh-Erbin-A1 shRNA. Additionally, using 
the three CRC cell lines with both sh-Erbin knockdown constructs, the effect of Erbin loss 
on cell proliferation in normal 2D culture was analyzed. Cells were lifted from a culture 
plate by trypsin treatment, counted, and an equal number of cells were plated and allowed 
to grow for 72 hours at which point a crystal violet assay to determine relative cell growth 
was performed. This assay uses crystal violet to stain the protein of the cells that grew over 
the 72 hour time period, it is solubilized with 1%SDS solution, and the amount of staining 
(which should be representative of the total number of cells) is quantified with a plate 
reader. The results from the crystal violet assay show that loss of Erbin did not have an 
effect on proliferation (Figure 3.5 B and C).  
3.2.5 Loss of Erbin increases amplitude and duration of signaling 
To further examine the effect of Erbin-loss on the temporal activation of signaling, 
stable control and Erbin knockdown SW480 cells were starved for 16 hours and 
subsequently stimulated with EGF for the indicated time (Figure 3.6 A). Once again we 
monitored activity of both the Akt and ERK signaling pathways, via Western blotting for 
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the activating phosphorylation events of each protein. Knockdown of Erbin increased both 
the amplitude and the duration of signaling through the Akt and several steps of the 
RAF/MEK/ERK pathways (Figure 3.6 B). Similar results, with increases in amplitude and 
duration of signaling through both pathways, were obtained in EGF-treated LIM2045 cells 
(Figure 3.6 C).  These results indicate that endogenous Erbin is inhibiting signaling through 
both of these oncogenic pathways. Increased signaling through these pathways is often 
associated with phenotypic changes within the cell, and these data led us to make further 
observations on the functional changes within the Erbin knockdown cells.  
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Figure 3.5 Knockdown of Erbin in CRC cells increases Akt and RAS/RAF signaling 
(A) Cell lysates prepared from stable control (sh-Control) and Erbin knockdown (sh-Erbin) 
cells, including Caco2, LIM2405 and SW480, were analyzed for the expression of Erbin 
and the phosphorylation status of Akt, MEK and ERK using Western blot. Two different 
shRNA targeting sequences (A1 and A2) were used to silence Erbin in each cell line. The 
relative phosphorylation of Akt, MEK and ERK was quantified by normalizing ECL 
signals generated by the phospho-specific antibodies to that of total proteins. (B) and (C) 
Stable control and Erbin knockdown Caco2, LIM2405, and SW480 cells (generated from 
sh-Erbin-A1 or sh-Erbin A2 targeting lentivirus) were cultured for 72 hours, and the 
relative cell growth was determined using crystal violet staining.  
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Figure 3.6 Knockdown of Erbin in SW480 cells increases the amplitude and duration 
of Akt and RAS/RAF signaling  
(A) Stable control and Erbin knockdown SW480 cells were stimulated with EGF (10 
ng/mL) for the indicated times and activation of signaling molecules were analyzed using 
Western blot. (B) The relative levels of p-Akt, p-MEK and p-ERK in sh-Control and sh-
Erbin SW480 cell lines were quantified by normalizing ECL signals generated by the 
phospho-specific antibodies to that of total proteins and plotted over the EGF stimulation 
time course. (C) EGF-induced activation of RAS/RAF signaling in sh-Control and sh-Erbin 
(A2) LIM2405 cells. Cells were stimulated with EGF (10ng/mL) for the indicated times 
and activation of signaling molecules were analyzed by Western blot.   
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3.2.6 Reduction of Erbin results in loss of epithelial cell polarity 
We next analyzed functional effects of silencing Erbin by using a 3D cell culture 
system. This system allows the cells to grow in a more physiologically relevant 
environment and allows us to determine if the loss of Erbin can alter growth in a 3-
dimensional matrix. In our system, Control and Erbin knockdown Caco2 and SW480 cells 
were seeded into 3D Matrigel and allowed to grow for 10 days to form tumor spheroids. 
As described in previous studies [28-30], control Caco2 cells were able to form acini-like 
spherical structures with a single hollow lumen, which consisted of a layer of polarized 
epithelial cells as indicated by the apical localization of F-actin (Figure 3.7 A). In marked 
contrast, Erbin depletion altered the acinar structure by inducing the formation of multiple 
lumens (Figure 3.7 A). Moreover, although not fully polarized, control SW480 cells were 
able to form tumor spheroids with partially hollowed lumens; however, cell clusters formed 
by Erbin knockdown SW480 cells lacked lumen structure and exhibited no apical or 
basolateral differentiation (Figure 3.7 A). Together, these results suggest that Erbin plays 
an important role in maintaining epithelial polarity.  
Furthermore, we found that knockdown of Erbin markedly increased the size of the 
spheroids in both Caco2 and SW480 cells (Figure 3.7 B). Diameter of the spheroids was 
measured using phase imaging of the control and knockdown cells, along with Nikon 
Elements software. To determine if decreased Erbin expression alters cell proliferation in 
3D culture, tumor spheroids formed by control and Erbin knockdown SW480 cells were 
labeled with EdU to mark proliferating cells (Figure 3.7 C). Quantitative results showed 
that loss of Erbin expression increased cell proliferating (Figure 3.7 D). These results differ 
from cell growth performed in traditional 2D culture, which showed no difference in cell 
growth upon loss of Erbin. A more physiologically relevant system, such as growth in 3D 
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Matrigel, places different stresses upon the cells and thus may require higher Erbin levels 
to grow correctly, whereas those stresses are lacking in the 2D culture system.   
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Figure 3.7 Knockdown of Erbin disrupts epithelial cell polarity and increases cell 
proliferation 
(A) Stable sh-Control and sh-Erbin Caco2 and SW480 cells were cultured for 10 days in 
3D Matrigel. IF images were taken from cells stained with Alexa488-phalloidin (green) 
and DAPI (blue). Phase-contrast images were obtained using a Nikon TE2000 inverted 
microscope with 10X objective, scale bar, 50µm; and confocal images of stained cells were 
obtained using an Olympus FlowView FV1000 confocal laser-scanning microscope, scale 
bar, 10µm. (B) The diameter of 15-35 randomly chosen spheroids of sh-Control and sh-
Erbin Caco2 and SW480 cells were measured. Data represents the mean  SEM (* p<0.05 
t-test). (C) Stable sh-Control and sh-Erbin SW480 cells were labeled with EdU to mark 
proliferating cells. (D) The percentage of EdU-positive cells were quantified and expressed 
graphically. Data represents mean  SEM (* p<0.05 t-test).   
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3.2.7 Knockdown of Erbin results in EMT in CRC cells 
To determine the molecular mechanism by which Erbin-loss induces polarity 
defects and promotes cell proliferation in 3D culture, control and Erbin knockdown SW480 
spheroids were collected and analyzed by Western blot. Interestingly, these data indicated 
that the morphological changes observed in sh-Erbin cells were accompanied by the 
downregulation of E-cadherin (an epithelial cell marker) and upregulation of vimentin and 
N-cadherin (markers of fibroblasts/mesenchymal cells), suggesting that Erbin knockdown 
cells had undergone EMT (Figure 3.8 A). Notably, increases in both Akt and ERK 
activation were maintained in Erbin knockdown spheroids grown in 3D (Figure 3.8 A). 
Collectively, these data suggested that downregulation of Erbin disrupts epithelial polarity 
and induces epithelial to mesenchymal transition (EMT) through increases in Akt- and 
ERK-mediated oncogenic signaling.  
To further confirm the induction of EMT, SW480 cells grown in regular 2D culture 
were subjected to Western blot analysis. Similarly as the spheroids from 3D culture, Erbin 
knockdown cells grown in 2D had also undergone EMT as indicated by downregulation of 
E-cadherin and upregulation of vimentin (Figure 3.8 B).  
3.2.8 Loss of Erbin increases cell motility 
Since we have observed EMT-like phenotypes in Erbin knockdown colon cancer 
cells grown in 2D and in 3D, we next determined the role of Erbin in regulating cell 
motility. Mesenchymal cells are endogenously more motile when compared to epithelial 
cells, and for this reason the EMT associated with the knockdown of Erbin was 
hypothesized to also increase cell motility. To monitor single cell motility, time-lapse 
images of control and Erbin knockdown SW480 and LIM2405 cells were captured and the 
distances traveled of individual cells were determined using a Nikon BioStation. Erbin 
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knockdown cells were considerably more motile and average distances traveled by Erbin 
knockdown cells were significantly increased compared to the control cells (Figure 3.9 A-
B). Control cells migrated an average of 100µm and 75µm for the LIM2405 and SW480 
cells respectively, while the knockdown of Erbin increased the motility to approximately 
160µm for both cell lines. The observed increase in total distance traveled suggests that 
Erbin-loss can increase cell motility at the single cell level.  
In addition, control Erbin knockdown SW480 and LIM2405 cells were subjected 
to Transwell migration and invasion assays (Figure 3.10 A). We found that both Erbin 
knockdown SW480, LIM2405, and HT29 cells migrated significantly faster (with 
approximately a 3-fold, 2-fold, and 5-fold increase in the number of cells migrated 
respectively) than the control cells (Figure 3.10 B). To ensure that both shRNA constructs 
conferred an equal increase in cell motility, we silenced Erbin using the two different 
targeting shRNAs (A1 and A2) and observed comparable effects on promoting migration 
in SW480 cells (Figure 3.10 C). Furthermore, in an invasion assay, the knockdown of Erbin 
significantly increased the ability of SW480 cells to invade through Matrigel placed inside 
of the transwell insert (Figure 3.10 D), thus confirming that loss of Erbin promotes cell 
migration and invasion as a result of EMT.  
3.2.9 Loss of Erbin Increases Cell Motility via Activation of ERK Signaling 
Since knockdown of Erbin resulted in increases in signaling through both the Akt 
and RAS/RAF pathways in CRC cells, we investigated which signaling pathway was 
functionally connected with the upregulation of cell motility. To this end, pharmacological 
inhibition of signaling pathways was accomplished through the use of either PD98059, a 
specific MEK1 inhibitor, or MK2206 a specific inhibitor of Akt. Similarly as with other 
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Transwell assays, control and Erbin knockdown SW480 cells were starved overnight and 
simultaneously incubated with either 10μM MEK inhibitor or 1μM Akt inhibitor. 
Additionally, the inhibitors were also included in the chemoattractant containing medium 
for the duration of the assay. We observed that inhibition of the ERK pathway completely 
diminished any increase in motility resultant from the loss of Erbin, while the Akt inhibitor 
had little to no effect (Figure 3.11).  
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Figure 3.8 Erbin knockdown results in EMT in 2D or 3D culture systems 
(A) Stable sh-Control and sh-Erbin SW480 cells were cultured for 10 days in 3D Matrigel 
and spheroids were collected and analyzed by Western blot for the expression of EMT 
markers. (B) Stable sh-Control and sh-Erbin SW480 cells grown in 2D culture were 
analyzed for the expression of Erbin, E-cadherin and Vimentin. 
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Figure 3.9 Knockdown of Erbin increases cell motility in CRC cells 
(A) Migration paths of stable sh-Control and sh-Erbin SW480 and LIM2405 cells were 
monitored using the Nikon Biostation for 6 hours. The trajectories of 12 randomly chosen 
cells for each cell line were shown in the graphs. (B) The averaged Path lengths were 
quantified for sh-Control and sh-Erbin LIM2405 and SW480 cells. Data represents mean 
 SEM (* p<0.05).  
  
  70 
  
  71 
Figure 3.10 Knockdown of Erbin increases CRC cell motility in Transwell assays 
(A) CRC cells are placed into the upper chamber of the Transwell and allowed several 
hours to migrate towards the lower chamber which contains a chemoattractant. The cells 
that were able to migrate to the lower side of the membrane are then fixed, stained with 
crystal violet, and counted. Image modified from Keenan and Folch, 2008 [146]. (B) Stable 
sh-Control and sh-Erbin SW480, LIM2405, and HT29 cells were subjected to Transwell 
migration assays using collagen and EGF (10ng/mL) as chemoattractants. The number of 
migrated cells per field of view were counted. Data represents mean  SEM (n=4, # 
p<0.0001). (C) Stable sh-Control and sh-Erbin SW480 cells (generating using both A1 and 
A2 targeting lentivirus) were subjected Transwell migration assays. The number of 
migrated cells per field of view were counted. Data represents mean  SEM (n = 3, * p<0.05 
and # p<0.0001). (D) Stable sh-Control and sh-Erbin SW480 cells were subjected to 
Transwell invasion assays using 5% FBS as the chemoattractant. The number of invaded 
cells per field of view were counted. Data represents mean  SEM (n=3, # p<0.0001).  
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Figure 3.11 ERK/MAPK signaling results in higher CRC motility. 
Stable sh-Control and sh-Erbin SW480, LIM2405, and HT29 cells were subjected to 
Transwell migration assays using collagen and EGF (10ng/mL) as chemoattractants. 
Treated cell lines were treated with 10μM PD98059 (MEK1 inhibitor) or 1μM MK2206 
(Akt inhibitor) overnight and additionally during the 4.5 hours while cells are within the 
Transwell chamber. The number of migrated cells per field of view were counted. Data 
represents mean  SD (*, p<0.05).   
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3.2.10 Erbin disrupts KSR1 and RAF1 interactions 
 To define the molecular mechanism underlying Erbin-mediated inhibition of 
RAF/MEF/ERK signaling activation, we performed experiments examining the possible 
interactions of Erbin and pro-signaling scaffold proteins within the same pathway. One of 
the proteins that we identified as a possible interaction partner of Erbin was Kinase 
Suppressor of Ras 1 (KSR1). KSR1 is known to facilitate the formation of RAF/MEK/ERK 
complex upon RAS activation [21]. We performed co-immunoprecipitation experiments 
to determine if Erbin expression affects the interaction between KSR1 and RAF1. 293T 
cells transfected with Flag-RAF1 in the presence or absence of CFP-KSR1 and Myc-Erbin 
were immunoprecipitated with the anti-Flag antibody. The overexpressed and endogenous 
KSR1 were found to pull-down with RAF1 (Figure 3.12 A). However, co-expression of 
Erbin largely reduced the amount of KSR1 immunoprecipitated with RAF1 (Figure 3.12 
A-B). In addition, to determine the interaction between endogenous Erbin and KSR1 
directly, co-immunoprecipitation experiments were performed in LIM2405 cells using 
antibodies against Erbin. Indeed, we found that endogenous KSR1 was co-
immunoprecipitated with Erbin (Figure 3.12 C).  
3.2.11 Erbin displaces KSR1 from the signaling complex and inhibits signaling 
To gain additional insight into the functional effect of Erbin-KSR1 interaction, we 
examined if Erbin may disrupt KSR1/RAF1 complex. Co-immunoprecipittion experiments 
were performed using control and Erbin knockdown CRC cells as shown in Figure 3.13 A. 
A graphic representation of known KSR1 interacting proteins is shown in Figure 3.13 B. 
Results from these co-immunoprecipitation experiments demonstrated that the formation 
of KSR1-RAF1 complex was increased in both Erbin knockdown Caco2 and LIM2405 
cells (Figure 3.14 A). Furthermore, we found that Erbin-loss induced an increase in ERK 
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activation that was abolished in cells where KSR1 was also silenced (Figure 3.14 B). The 
effect of silencing Erbin, KSR1 or in combination on ERK signaling was analyzed; and the 
results showed that Erbin knockdown induced increase in ERK activation was eliminated 
when KSR1 was depleted as well, thus confirming the functional interplay between Erbin 
and KSR1 in regulating RAF/MEK/ERK signaling. Collectively, these results suggest that 
Erbin functions to prevent KSR1 from forming a signaling complex with RAF1 and inhibits 
signaling activation downstream of RAF1.   
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Figure 3.12 Erbin disrupts the interaction between KSR1 and RAF1 
(A) 293T cells transfected with Flag-RAF1 and CFP-KSR1 in the presence or absence of 
Myc-Erbin co-expression were lysed and immunoprecipitated with Flag-affinity beads. 
The presence of KSR1 and Erbin in the immunoprecipitates were detected by Western blot. 
The arrow indicates the endogenous KSR1 co-immunoprecipitated by Flag-RAF1. (B) The 
relative amount of KSR1 co-immunoprecipitated with RAF1 in the presence or absence of 
Myc-Erbin co-expression was quantified and expressed graphically (n=3, * p<0.05). (C) 
Erbin interacts with endogenous KSR1. Endogenous Erbin was immunoprecipitated from 
LIM2405 cell lysates and the presence of KSR1 in the immunoprecipitates was detected 
by Western blot.   
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Figure 3.13 KSR1 and RAF1 immunoprecipitation schematic 
(A) Stable control or Erbin knockdown CRC cells were lysed and RAF1 is 
immunoprecipitated from the cells. The levels of co-immunoprecipitated KSR1 were then 
determined, with the varying levels of Erbin. (B) A graphic representation of the interaction 
that occurs between KSR1 and members of the RAS/RAF pathway. The presence of KSR1 
facilitates the phosphorylation cascade to enhance signaling activation.  
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Figure 3.14 Erbin displaces KSR1 from the positive RAF1 signaling complex   
(A) Endogenous RAF1 was immunoprecipitated from sh-Control and sh-Erbin Caco2 and 
LIM2405 cells. The levels of KSR1 co-immunoprecipitated with RAF1 were detected by 
Western blot. (B) The expression of KSR1 and Erbin were silenced individually or in 
combination in SW480 cells using corresponding shRNA lentivirus. Cell lysates were 
analyzed for the phosphorylation status of ERK. The relative levels of ERK 
phosphorylation in different cells were quantified by normalizing ECL signals generated 
by p-ERK to that of total proteins.   
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3.2.12 Summary of In Vitro Studies  
Collectively, results from our in vitro studies suggest that Erbin plays an important role in 
inhibiting EMT and oncogenic signaling in CRC cells. 
 The Erbin expression levels, including both mRNA and protein, are decreased in 
patient tumor tissues when compared to the levels in normal colon tissue.  
 Knockdown of Erbin increases signaling through both the Akt and RAS/RAF 
pathways in CRC cell lines.  
 The loss of Erbin results in loss of epithelial polarity, increased cellular motility 
and EMT.  
 Erbin disrupts the function of a pro-signaling scaffold protein, KSR1, and reduces 
the activation of oncogenic signaling cascade in cancer cells.  
3.2.13 Erbin Knockout reduces lifespan of Apc mice 
To determine the effect of Erbin-loss on tumorigenesis of CRC in vivo, we crossed 
Erbin-null mice with the Apcf/f/Vil-cre mouse model [31] to investigate the susceptibility 
of mice deficient in Erbin to Apc-driven intestinal adenomas. Erbin knockout (KO) mouse 
models have been used in previous studies to investigate the role of Erbin in inflammatory 
responses and cardiac hypertrophy [32, 33]. However, no reports have been made that the 
knockout of Erbin alone results in the development of spontaneous tumors. To understand 
the role of Erbin on tumorigenesis, studies have paired the Erbin KO mouse model with a 
tissue specific tumor-initiating mutation, such as mutant Kras-driven skin tumorigenesis 
model [147]. For this reason, we chose to cross the Erbin KO mouse with the well-
established Apcf/f/Vil-cre mouse model and monitor the initiation and progression of the 
intestinal tumors.  The active promoter of Villin, an intestinal specific protein, drives the 
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transcription of the Cre-recombinase in the intestines, which leads to the removal of the 
floxed Apc gene. This loss of tumor suppressor Apc is very similar to the mutations that 
occur in human CRC initiation and leads to upregulation of Wnt signaling in the intestinal 
epithelia, eventually leading to hyperproliferation and formation of adenomas.   
To specifically assess the role of Erbin in tumor initiation and progression in 
intestinal epithelium, we crossed Erbin KO mice onto the Apc mutant background to 
generate the following three cohorts of mice: Apcf/+/Vil-Cre/Erbin+/+, Apcf/+/Vil-
Cre/Erbin+/- and Apcf/+/Vil-Cre/Erbin–/– (Apc/WT, Apc/Het, and Apc/KO, respectively). 
Survival studies showed that knockout of a single allele of Erbin was sufficient to markedly 
accelerate the tumorigenesis process, resulting in a significantly shorter lifespan when 
compared to Apc/WT mice (Figure 3.15). Knockout of both alleles of Erbin further 
accelerated this process and significantly decreased survival (Figure 3.15). The mean 
survival times for the Apc/WT, Apc/Het, and Apc/KO were over 180 days, 132 days, and 
77 days respectively. In addition to recording the survival times for each cohort of mice, 
we also made swissrolls from the intestines. This included opening up the intestines 
longitudinally and rolling the intestine from the distal end towards proximal, creating 
several layers of intestine, which were then paraffin embedded (Figure 3.16 A). 
Histopathological analysis of the swissrolls revealed that adenomas were detected in both 
intestine and colon regions in all three cohorts of mice.  While the mice from the different 
cohorts had significant changes in survival time, the cohorts had an equal tumor number 
and tumor burden when the mice presented with “end of life” symptoms (hunched stature 
and rectal bleeding). However, when Apc/WT mice were sacrificed at time points that 
corresponded to average lifespan of Apc/Het and Apc/KO mice (4.5 and 2 month, 
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respectively), it was apparent that the tumor burdens were increased in Apc/Het and 
Apc/KO mice compared to Apc/WT mice (Figure 3.16 B). The difference in tumor burdens 
was particularly clear in Apc/KO mice, in that more than half of mice in this cohort reached 
maximum tumor burdens at 2 month when no tumors were detected in Apc/WT mice 
(Figure 3.16 B).   
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Figure 3.15 Erbin deletion decreases survival in Apc mutant mice 
Erbin-loss significantly reduces the lifespan of Apc mutant mice. Kaplan-Meier curve 
shows the survival distribution of three cohorts of mice: Apcf/+/Vil-Cre/Erbin+/+, 
Apcf/+/Vil-Cre/Erbin+/- and Apcf/+/Vil-Cre/Erbin–/– (Apc/WT, Apc/Het, and Apc/KO, 
respectively). Numbers of mice in the three cohorts are: Apc/WT (n=14), Apc/Het (n=16) 
and Apc/KO (n=8). Statistical significance (determined by Log Rank test) is given for 
comparisons between Apc/WT and Apc/Het (p<0.0001) and Apc/WT and Apc/KO 
(p<0.0001).   
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Figure 3.16 Erbin deletion decreases survival and increases tumorigenesis in Apc 
mutant mice 
(A) A representative image of a “swissroll” made from mouse intestines. Modified from 
Colnot et al. 2004 [148] (B) Histology analysis of intestinal adenomas of Apc/WT and age-
matched Apc/WT and Apc/Het mice (at 4.5 months) as well as Apc/WT and Apc/KO mice 
(at 2 months). Scale bar, 200μm.   
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3.2.14 Knockout of Erbin increases cell signaling in both tumor organoids and MEF cells  
In order to further explore the mechanisms for the observed increase in 
tumorigenesis, tumor cells isolated from Apc/WT and Apc/KO mice were allowed to grow 
into tumor organoids in 3D Matrigel. This culture system lacks several medium additives 
necessary for the growth of normal epithelial tissue, and therefore selects for only growing 
the tumors within the mouse intestines. These organoids are comprised of adenoma cells 
which form cystic structure without budding (Figure 3.17 A). To determine if Erbin inhibits 
signaling in mouse adenomas, protein lysates prepared from tumor organoids were 
subjected to Western blot analysis. Both Akt and ERK phosphorylation were markedly 
increased in Erbin KO organoids (Figure 3.17 B). Moreover, consistent with results 
obtained in CRC cells, we found that the amplitude and duration of EGF-stimulated Akt 
and RAF/MEK/ERK signaling were largely increased in Erbin KO MEF cells (Figure 3.17 
C). Together, these data showed that Erbin-loss promotes the activation of Akt and 
RAF/MEK/ERK signaling and tumorigenesis in mouse models of CRC. 
3.2.15 Normal epithelial cells are not significantly different in Erbin KO mice 
Since the knockout of Erbin alone did not result in the development of spontaneous 
tumors we were interested in determining whether there were differences in normal 
intestinal growth and differentiation. Intestinal tissue from Erbin WT, heterozygous, and 
KO mice were collected, and these tissues were then made into swissrolls and IHC stained 
for various protein markers for proliferation and cell lineages. We compared the 
proliferation and differentiation of normal intestinal epithelial cells in WT, heterozygous 
and Erbin KO mice and found no difference in the number of proliferating cells and 
differentiated cells of different cell linages (Figure 3.18).  
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3.2.16 Erbin Knockout does not alter gene expression in normal intestinal organoids 
In addition to collecting normal epithelial tissue for IHC staining, we also grew 
these cells in 3D culture. We were able to propagate these cells and collect them for 
analysis via qPCR, further analyzing any differences in stemness, differentiation, or 
proliferation. Consistent with the lack of changes observed IHC staining, normal intestinal 
tissues were cultured in Matrigel no significant differences were observed in the resulting 
organoid shape or size (Figure 3.19 A). Similarly, the expression of genes associated with 
normal intestinal stem and differentiated cells remained unchanged in intestinal organoids 
derived from Erbin heterozygous and homozygous KO mice compared to WT mice (Figure 
3.19 B).  
3.2.17 Erbin Knockout significantly increases the stemness in tumor organoids 
We next analyzed the tumor initiation capacity of mouse tumor organoids using the 
colony formation assay. Apc/WT and Apc/KO organoids were dissociated into single cells 
and re-seeded into Matrigel. The number of tumor organoids formed was counted after 5 
days in culture. Knockout of Erbin resulted in a two-fold increase in organoid formation 
(Figure 3.20 A). Since increased tumor initiation capacity is often associated with cancer 
stem cells, our results suggest that Erbin-loss may enhance stem-like properties in tumor 
organoids.  
To test the hypothesis that Erbin may influence the stemness of tumor derived 
organoids, we determined the profile of stem cell gene expression using quantitative RT-
PCR analysis. Apc/WT and Apc/KO organoids were grown in 3D culture for 5 days and 
then were collected and analyzed for the expression of genes that are typically associated 
with cancer stem cells (eg. Lgr5, Axin2, and Cd44), intestinal cell differentiation (eg. Alpi, 
Fabp2, and Muc2), and cell proliferation (eg. Ccnd1 and Ki67). The tumor organoids 
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derived from Apc/KO mice expressed higher levels of genes associated with stem cells and 
cell proliferation, which coincided with decreased expression of genes associated with 
differentiated intestinal epithelial cells (Figure 3.20 B). These data would suggest that the 
loss of Erbin is resulting in an increase in adenoma cell stemness, and these changes are 
likely the underlying cause for the observed increase in the organoid tumor-initiation assay 
and the earlier occurrence of tumorigenesis in the Apc/KO mice. Additionally, we also 
made similar observations in tumor organoids derived from the Apc/Het mice, where the 
expression of genes associated with stem cells and cell proliferation were significantly 
increased and intestinal differentiation decreased (Figure 3.20 C), confirming that 
haplodeficiency of Erbin is sufficient to promote tumorigenesis.   
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Figure 3.17 Erbin deletion activates Akt and RAS/RAF signaling in Apc mutant mice  
(A) Tumor organoids were prepared from tumor tissues of Apc/WT and Apc/KO mice and 
grown in 3D Matrigel. Scale bar, 200μm. (B) Cell lysates were prepared from tumor 
organoids as shown in (A) and analyzed for the phosphorylation status of Akt and Erk by 
Western blot. (C) MEF cells generated from WT and Erbin KO mice were stimulated with 
EGF (10ng/mL) for the indicated times and analyzed for the activation of Akt and 
RAS/RAF signaling by Western blot.   
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Figure 3.18 Knockout of Erbin has no significant effect on the proliferation and 
differentiation of normal intestinal epithelial cells 
Swiss rolls of intestinal tissues from WT, Erbin+/- (Het) and Erbin-/- (KO) mice were 
analyzed for the appearance of normal crypt-villus structure using H&E staining. Alcian 
blue and PAS staining were used to identify goblet cells and Paneth cells; whereas Ki67 
and chromogranin A IHC staining detects proliferating cells and enteroendocrine cells, 
respectively. Scale bar, 200μm.  
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Figure 3.19 Loss of Erbin does not significantly alter the expression of genes 
associated with intestinal stem cells and differentiation in normal intestinal organoids 
(A) Representative phase contrast images of intestinal organoids derived WT and Erbin-/- 
(KO) mice grown in 3D Matrigel for 5 days. Scale bar, 200μm. (B) Intestinal organoids 
from WT, Erbin+/- (Het) and Erbin-/- (KO) mice were grown in 3D Matrigel and collected 
after 5 days. Total RNA were prepared and used for qRT-PCR analysis for the expression 
of genes associated with intestinal stem and progenitor cells (Lgr5, Axin2 and Cd44), cell 
proliferation (Ccnd1 and Ki67) and intestinal cell differentiation (Alpi, Chga, Muc2 and 
Cdh1). Data represents mean  SEM, n=3.   
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Figure 3.20 Loss of Erbin enhances cancer stem cell properties in tumor organoids 
(A) Tumor organoids derived from Apc/WT and Apc/KO mice were dissociated into single 
cells and 1,000 cells were reseeded in 3D Matrigel. The number of cells that were able to 
successfully form colonies were quantified. Data represents mean  SEM (n=3, * p<0.05). 
(B) Tumor organoids derived from Apc/WT and Apc/KO mice grown in 3D Matrigel for 
72 hours were collected and analyzed for the expression of genes associated with cancer 
stem cells (Lgr5, Axin2 and Cd44), cell proliferation (Ccnd1 and Ki67) and intestinal 
differentiation (Alpi, Fabp2 and Muc2) using quantitative RT-PCR. (C) Tumor organoids 
derived from three cohorts of mice (Apc/WT, Apc/Het and Apc/KO) were grown in 3D 
culture for 72 hours, collected, and analyzed using qRT-PCR for the expression of genes 
associated with cancer stem cells (Lgr5 and Axin2), cell proliferation (Ccnd1, Ki67) and 
intestinal cell differentiation (Fabp2). Data represents mean  SEM (n = 4, * p<0.05 and # 
p<0.0001).  
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3.2.18 Gene Set Enrichment Analysis confirms Erbin’s role in colorectal cancer 
Since cancer stem cell associated genes, such as Lgr5 and Cd44, are targets of Wnt 
signaling, our data suggested that Erbin-loss results in activation of the Wnt pathway in 
Apc mutant tumors. Furthermore, through a collaboration with the Markey Cancer Center 
– Biostatistics and Bioinformatics Shared Resource Facility, we analyzed if Erbin 
expression is associated with cancer-related biological pathways by analyzing gene 
expression data from the Cancer Genome Atlas (TCGA) CRC RNA-seq dataset. Gene Set 
Enrichment Analysis (GSEA), several example gene sets that were analyzed, and the 
resulting distribution of association is shown in Figure 3.21 A. The actual results from the 
GSEA showed Erbin expression associated with several pathways, including a positive 
association with the E-cadherin adherens junction (AJ) pathway and Erbin negatively 
associated with Wnt signaling (Figure 3.21 B). These data support our findings that loss of 
Erbin promotes the disruption of epithelial polarity by reducing E-cadherin expression and 
enhances cancer stem cell property by increasing signaling through the Wnt pathway. 
Taken together, our results showed that genetic deletion of Erbin promotes tumor formation 
and progression in vivo upon activation of Akt and ERK signaling. Loss of Erbin enhances 
the stem-like characteristics in tumor organoids and potentiates tumor initiation.  
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Figure 3.21 Gene Set Enrichment Analysis confirms Erbin’s role in control epithelial 
junctions and Wnt signaling 
(A) An example of several gene sets that correlate the expression of Erbin in CRC patients 
by analyzing RNA-seq data obtained from the TCGA database. The genes in each gene set 
are analyzed and determined to have a positive or negative association with Erbin, which 
can be quantified for each gene set to determine if Erbin expression is correlated to any 
signaling or physiological pathways (B) Gene Set Enrichment Analysis was performed and 
the enrichment plots showed significant correlation with the E-cadherin pathway (NES = 
2.32, FDR <0.0001) and Wnt signaling (NES = –2.65, FDR <0.0001) with Erbin 
expression in CRC patients.   
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In summary, the collection of data provides strong evidence confirming the role of 
Erbin as a tumor suppressor in CRC. Previous data had shown that Erbin could interact 
with many proteins at cell-cell junctions and alter ERK signaling, which resulted in some 
physiological consequences in normal cell differentiation. However, while Erbin’s role in 
cancer has not been as thoroughly explored, with some publications concluding that Erbin 
may be a tumor promoter, the data collected in my dissertation studies would help confirm 
a tumor suppressor role. By playing an important role in maintaining epithelial cell polarity, 
Erbin functions as a negative scaffold to directly inhibit oncogenic signaling at multiple 
steps, thus effectively inhibiting tumorigenesis and progression (Figure 3.22). 
Mechanistically, these data have shown that Erbin can alter KSR1/RAF1 interactions and 
suppress ERK signaling, strengthening the idea that Erbin is a negative-regulating scaffold 
protein.  
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Figure 3.22 Erbin inhibits tumorigenesis and progression of CRC 
A diagram showing the mechanism underlying Erbin-mediated tumor suppressor function 
in CRC. Our study demonstrates that loss of Erbin expression promotes tumor progression 
as a result of increased RAS/RAF and Akt signaling. Basolateral expression of Erbin in 
normal epithelial cells prevents hyperactivation of RAS/RAF signaling by sequestering 
KSR1 from binding RAF1. In addition, Erbin may inhibit Akt activation by suppressing 
ERBB2 function.  
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3.3 Other roles for Erbin in regulating cell signaling 
3.3.1 Erbin alters ErbB2/EGFR signaling 
 In addition to examining Erbin-mediated inhibition of RAF/MEK/ERK signaling 
through a KSR1-dependent mechanism, we also conducted experiments to test the 
hypothesis that Erbin-loss induced polarity defect may activate EGFR signaling directly. 
EGFR and EGF-like ligands are known to be over-expressed or mutated in many cancers 
including CRC, as well as breast, prostate, kidney, ovary, brain, pancreas, bladder, and 
lung [149, 150]. Stimulation of EGFR primarily leads to the activation of RAS/RAF 
signaling that is known to mediate multiple processes involved in tumor progression, 
including angiogenesis, invasion, migration, proliferation, and evasion of apoptosis [151].  
 Erbin directly interacts with ErbB2, this interaction is required for basolateral 
localization of ErbB2, and ErbB2 is a preferred signaling partner of other ErbB family 
receptors including EGFR [73]. EGFR-ErbB2 heterodimers enhance signaling due to 
evasion of receptor endocytosis and degradation [152]. Additionally, previous research 
studies have shown that the loss of polarity can lead to aberrant activation of receptor 
tyrosine kinases (RTK) due to disruption of asymmetrical distribution of the receptors 
[153]. In the case of EGFR, it is well established that the expression and localization of 
EGFR is highly restricted to the basolateral plasma membrane in polarized epithelial cells 
[154]. The basolateral distribution of the receptors is not only responsible for proper 
activation but also for the degradation and appropriate quenching of the signal. Following 
EGFR stimulation, the receptor undergoes ligand-induced receptor endocytosis initialized 
by the receptors diffusing laterally through the membrane to localize within clathrin-coated 
pits [155]. Redistribution to coated pits is necessary to internalize multiple activated 
receptors in one vesicle, and once multiple EGFRs are located within that pit, they are 
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rapidly internalized [156, 157]. The results of this process are either the eventual 
degradation of the receptor and the associated growth factor in the lysosome, or the 
recycling of the receptor back to the plasma membrane where it can be activated once again 
[158]. This process can therefore lead to the attenuation of signaling by removing actively 
signaling receptors and degrading them, as well as reducing the total number of receptors 
available for subsequent ligand activation on the cell surface [159, 160]. 
 Mechanistically, after receptor stimulation, EGFR cytoplasmic tail tyrosines are 
phosphorylated and it is through the interactions between these auto-phosphorylation sites 
and a variety of adapter proteins that allow for specificity in the cellular response (Figure 
3.23).   
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Figure 3.23 EGFR phosphorylation sites 
The multiple phosphorylation sites on the cytoplasmic tail of the EGF Receptor are 
involved in the recruitment and activation of many different adapter proteins, which lead 
to activation of various downstream pathways. 
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 Two examples of physiological processes that are dependent on the recruitment of 
these adapter/interacting proteins after EGFR stimulation include the activation of the 
RAS/RAF and Akt pathways which requires the recruitment of Grb-2. Also, for 
degradation or recycling of EGFR to occur, a recruitment of the E3-ligase, c-Cbl, to the 
activated receptor is required. Additionally, it is not clear whether altered receptor 
distribution as the result of disruption of apical-basal polarity may contribute to the 
hyperactivation of EGFR signaling in CRC. 
3.3.2 The role of Erbin in EGFR expression, internalization and degradation 
  To date, it is not known whether Erbin is involved in regulating EGFR. Therefore 
to begin to determine if the disruption of polarity resulting from the loss of Erbin has an 
effect on EGFR signaling, we investigated the time course of EGFR phosphorylation and 
internalization using CRC cell lines, including SW480, Caco2, LIM2405, and DLD1, as 
well as MEF cells. The expression of Erbin was silenced using lentivirus-mediated RNAi 
in CRC cell lines. Control and Erbin knockdown cells were treated EGF for 0-45 minutes. 
Similarly, WT and Erbin KO MEF cells were used with EGF stimulation. Here, we 
monitored EGFR activity, via Western blot for phosphorylation at several sites on the 
cytoplasmic tail. Unexpectedly the phosphorylation of EGFR at the Y1068 site (Figure 
3.24) was markedly reduced in the Erbin knockdown cells. Notably, the altered EGFR 
phosphorylation site is involved in the recruitment of c-Cbl (Figure 3.23). In addition to 
observing phosphorylation differences at the EGFR level, in all CRC cell lines with 
reduced levels of Erbin we also noted decreased total protein levels of EGFR, ErbB2, and 
ErbB3 (ErbB4 was undetectable in CRC cells). Contrarily, the Erbin KO MEF cells had 
dramatically increased levels of EGFR and phosphorylation at the Y1068 site (Figure 
3.25). Further experiments are required to fully understand the differences in signaling, but 
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could possibly be due to the presence/absence of certain adapter proteins in the different 
cell systems. 
 To further analyze if altered EGFR phosphorylation in Erbin knockdown cells 
affects the internalization of EGFR, we monitored the time course of EGFR endocytosis 
upon treating cells with Alexa 488-labeled EGF using immunofluorescence imaging. 
Interestingly, as shown in Figure 3.26, abundance of fluorescent-labeled EGF was found 
on the cell surface after treating cells for 4 minutes in Erbin knockdown cells indicating 
decreased endocytosis of EGFR. In addition, the knockdown cells showed attenuated 
degradation of the green fluorescent signal suggesting a slower rate of EGFR trafficking to 
the lysosome. 
 In summary, the disruption of epithelial polarity as a result of Erbin downregulation 
may alter the time course of EGFR activation. Despite differential effects were observed 
on EGFR phosphorylation upon Erbin depletion in different cell lines, Erbin-loss 
consistently activates RAS/RAF signaling downstream of EGFR. However, future studies 
are needed to further determine the molecular mechanism underlying Erbin-mediated 
regulation of EGFR at the receptor level.   
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Figure 3.24 Knockdown of Erbin in SW480 decreases EGFR phosphorylation 
Stable sh-Control and sh-Erbin SW480 cells were stimulated with EGF (10 ng/ml) for the 
indicated times and activation of signaling pathways and EGFR phosphorylation (Y1068) 
were analyzed via Western blotting. While Erbin knockdown cells have decreased 
phosphorylation of EGFR, downstream proteins such as ERK and Akt both show increased 
and prolonged phosphorylation and activation.   
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Figure 3.25 Knockdown of Erbin increases EGFR levels and phosphorylation in MEF 
cells 
Wildtype and Erbin KO MEF cells were stimulated with EGF (10 ng/ml) for the indicated 
times and activation of signaling pathways and EGFR phosphorylation (Y1068) were 
analyzed via Western blotting. Interestingly, Erbin KO cells have increased total levels and 
phosphorylation of EGFR, which is not observed in CRC cells with reduced Erbin levels. 
However, regardless of EGFR phosphorylation, downstream proteins such as ERK and Akt 
both show similar increases in phosphorylation and activation.  
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Figure 3.26 Knockdown of Erbin alters EGFR distribution and internalization in 
SW480 cells 
The expression pattern of EGFR in sh-Control and sh-Erbin SW480 cells at 4, 15, and 30 
minutes after the cells were stimulated with Alexa-488 labeled EGF. Increases in 
fluorescent EGF bound at 4 minutes may be the result of more EGFR localized to the 
plasma membrane of Erbin knockdown cells. Also, slower degradation of EGF signal as 
observed at 30 minutes may indicate prolonged EGF-induced signaling in Erbin 
knockdown cells.   
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CHAPTER 4: DISCUSSION 
4.1 The Role of Erbin as a Tumor Suppressor in CRC 
Loss of epithelial polarity is a hallmark of advanced malignant tumors. Emerging 
evidence supports the notion that disruption of polarity promotes EMT and the malignant 
progression of cancer [15, 35, 36]. Several oncogenes and tumor suppressors (such as 
ErbB2, Kras, and Lkb1) are known for their ability to regulate cell signaling as well as the 
integrity of epithelial polarity [30, 37, 38]. In this study, combining in vitro and in vivo 
analyses, we identify Erbin as a tumor suppressor in CRC. Analysis of gene expression 
datasets revealed that Erbin mRNA expression in patient tumor tissue is significantly 
downregulated. Additionally, using Western blotting and immunohistochemical staining 
of patient tissues, we demonstrated that Erbin protein expression is decreased, and 
mislocalized, in the tumor specimens. Functionally, the knockdown of Erbin in CRC cells 
results in the disruption of epithelial cell polarity as observed through the formation of 
multiple lumen cell clusters with aberrant distribution of apical and basolateral proteins in 
3D culture. The loss of polarity is accompanied by an increase in cell proliferation as shown 
by increased spheroid size and the number of EdU positive cells per 3D tumor sphere. 
Moreover, knockdown of Erbin increases the amplitude and duration of signaling through 
both the Akt and RAF/MEK/ERK signaling cascades, inducing EMT in CRC cell lines. 
Consecutively, we observed significant increases in cell motility as measured by Transwell 
migration assays as well as with time-lapse live cell imaging and determined this motility 
to be associated with increased signaling through the MAPK. Using co-
immunoprecipitation experiments, we identified KSR1, a positive regulator of ERK 
signaling, as an interacting protein of Erbin. We showed that Erbin functions by displacing 
KSR1 from the RAF-MEK-ERK complex thus preventing signal transduction through the 
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ERK pathway. Furthermore, through the development of the Apc-Erbin knockout double 
mutant mice, we investigated the impact of Erbin-loss on intestinal tumorigenesis in vivo. 
The loss of Erbin expression in Apc mutant mice results in a significantly shorter lifespan, 
with a stepwise reduction in survival as each allele of Erbin is lost. To understand the 
mechanism of the increased tumorigenesis after Erbin knockout, tumor organoids from 
those mice were used to confirm increased Akt, RAS/RAF signaling, and interestingly the 
expansion of the stem-like tumor initiating cell population. Taken together, these results 
suggest that Erbin functions as a negative regulator of both EMT and cell motility by 
directly suppressing Akt and ERK signaling. Additionally, these data suggest that loss of 
Erbin expression promotes Wnt signaling and tumor formation in vivo. 
Previous studies have suggested that Erbin inhibits the activation of ERK by 
disrupting upstream Shoc2-mediated RAS/RAF interaction [92, 93]. However, Shoc2 is 
primarily localized to the cytoplasm and actively facilitates RAS/RAF signaling within 
endosomal compartments [59]. It remains an open question how Erbin, a protein that is 
primarily localized to the basolateral membrane, interferes with Shoc2-dependent 
activation of RAS/RAF signaling within the endosome. In our study, we show that Erbin 
decreases RAF/MEK/ERK signaling through directly competing with KSR1. KSR1 is 
known to translocate to the plasma membrane upon RAS activation [21, 22]. While results 
from our study and others demonstrate that Erbin is localized at the basolateral membrane, 
it is possible that Erbin could be localizing to multiple sub-domains of the plasma 
membrane and this could help explain how Erbin could have multiple inhibitory roles, such 
as with ErbB2, Shoc2, and KSR1. However, specifically for the KSR1 interaction, being 
in close proximity with receptor tyrosine kinases (such as EGFR and ErbB2) and the site 
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of RAS activation, the presence of Erbin likely blocks the access of KSR1 to RAS-bound 
RAF and reduces KSR1-RAF interaction (Figure 4.1). In our study, in addition to increased 
ERK signaling, the knockdown of Erbin induces activation of Akt in colon cancer cells and 
mouse tumor organoids. Pharmacological Akt inhibition was unable to decrease cell 
motility; however, we have not fully investigated the implications of increased Akt 
signaling after Erbin knockdown. Future studies would be necessary to determine if the 
loss of polarity, increased proliferation, or changes to Wnt signaling are downstream of 
Akt. The literature regarding signaling changes within the Akt pathway, specifically after 
Erbin loss, is inconsistent and seems to be dependent upon the cell type or system in which 
the study was performed [5, 34]. The differential effect of Erbin-loss on Akt activation may 
be due to protein interactions that are cell type specific.   
 In cells where silencing Erbin induces loss of epithelial polarity and EMT (such as 
in colon cancer cells), it may lead to mislocalization of receptor tyrosine kinases and 
aberrant activation of both Akt and ERK signaling downstream. The role of Erbin in 
receptor trafficking is vastly under studied. Erbin could inhibit signaling by altering ErbB 
family member protein trafficking or endocytosis, increasing degradation or resulting in 
fewer interactions with pro-signaling scaffolds (ie. Shoc2 and KSR1). Endogenous Erbin 
protein is mostly localized to the plasma membrane [85], where it directly interacts with 
ErbB2 and this interaction is required for the receptors basolateral localization [73] and 
ErbB2 is a preferred signaling partner of other ErbB family receptors including EGFR. 
Previous data has shown that EGFR-ErbB2 heterodimers exhibit increased signaling due 
reduced receptor endocytosis and degradation [152]. Therefore, since Erbin can alter 
ErbB2 localization, through heterodimer interactions Erbin could also alter the localization 
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of all ErbB family members. Through interactions with the C-terminal tail of ErB2 Erbin 
could change the signaling from these receptors whether that is through physically 
restricting the receptors to a sub-domain of the plasma membrane or by altering adapter 
protein interactions. In our studies we observed an EMT phenotype and a loss of polarity 
in the CRC cell lines, which could lead to the loss of proper receptor localization and 
aberrant activation of signaling downstream of receptors (Figure 4.2).   
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Figure 4.1 Erbin is a negative signaling scaffold protein in multiple pathways 
While Erbin was previously known to interact with the ErbB2 receptor, our data have 
shown that Erbin can also inhibit the RAS/RAF pathway through inhibition of KSR1 
facilitated signaling. Additionally, Erbin was shown to reduce transcription levels of Wnt 
target genes. Further studies will be necessary to determine exactly where in the Wnt 
signaling pathway Erbin is contributing to this regulation.    
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Figure 4.2 Loss of polarity induces malignant transformation of epithelial cells 
Once polarized, two adjacent intestine epithelial cells are connected by the tight and 
adherens junctions which separate the membrane into apical and basolateral domains. 
Erbin, ErbB2, and EGFR are basolateral membrane associated proteins. In polarized cells, 
only the receptors localized on the basolateral membrane are in contact with ligands in the 
microenvironment of stroma. When polarity is lost, cells undergo EMT and EGFR/ErbB2 
receptors can become mislocalized and hyperactivated.   
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 In our study, we find that Erbin-loss alters the time course of EGFR 
phosphorylation, and receptor trafficking and degradation. Our results in Figure 3.24 show 
that while there are reduced total levels of EGFR/ErbB2/ErbB3 in whole cell lysates there 
are also alterations in EGFR phosphorylation that could result changes to EGFR/adapter 
protein interactions. Additionally, in Figure 3.26, we show that loss of Erbin in SW480 
cells results in more EGF ligand binding at the cell surface. The results that total EGFR 
levels may be lower in CRC cells, while cell surface EGFR levels are higher and more 
sustained after EGF stimulation, suggests that Erbin may play a role in recruiting certain 
adapter proteins to the receptors and effecting receptor trafficking or sorting after 
endocytosis. However, knowing that the MEF cells had a very different response to the 
loss of Erbin (increased EGFR protein and phosphorylation levels) could lead us to 
conclude that the role of Erbin at the plasma membrane may depend upon the presence of 
a cellular junction or other interacting partners. These conflicting results, and possibility 
that other proteins are involved in the regulation, only make the role of Erbin in controlling 
RTK signaling more fascinating and more studies will be necessary to conclude if this 
process is involved in tumor progression and EMT.  
Intriguingly, knockout of Erbin in Apc mutant mice only resulted in an increase in 
tumorigenesis and are not sufficient to induce EMT phenotype as the expression of E-
cadherin remains unchanged in Apc/KO tumor tissues and organoids compared to Apc/WT 
(as seen by qPCR, data not shown). Additionally, as further evidence that Erbin KO is 
insufficient to induce an EMT phenotype, loss of Erbin in Apc tumor organoids does not 
result in a loss of polarity in 3D culture (Figure 3.17 A). Thus, additional oncogenic 
alterations, such as PIK3CA and KRAS mutations presented in human colon cancer cells, 
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are likely needed to fully engage the EMT program in Erbin deficient tumor cells. Studies 
using CRC cell lines with mutant KRAS, such as DLD1, along with DLD1 cells in which 
WT KRAS has been reintroduced would be useful to determine if mutational status could 
affect interactions between Erbin and its pro-signaling interacting partners, resulting in 
different signaling events.  
While the protein interactions and mechanistic roles for Erbin are relatively 
consistent, the role of Erbin in cancer has been controversial. A number of studies have 
shown that Erbin negatively regulates Akt and ERK signaling, as well as cell proliferation 
and survival in different types of cancer cells [7, 40], thus acting as a tumor suppressor. 
However, other studies have indicated that Erbin-loss increases tumorigenesis [34, 41], 
resulting in the conflict within the field. Results from our study have provided several lines 
of evidence supporting the tumor suppressor function of Erbin in CRC: i) analysis of 
human CRC gene expression datasets with large sample sizes indicates that Erbin mRNA 
expression is significantly downregulated in CRC patients; ii) Erbin protein expression is 
decreased in CRC patient specimens by Western blot and IHC analyses; iii) knockdown of 
Erbin disrupts epithelial polarity and promotes EMT to increase cell motility; iv) knockout 
of Erbin in Apc mutant mice promotes tumor progression and significantly reduces 
survival; and v) tumor organoids derived from Erbin KO mice have increased cancer-stem 
cell properties and Wnt signaling. Our findings are also corroborated by the GSEA analysis 
in which Erbin expression is found to be associated with increased E-cadherin junctions 
and decreased Wnt signaling. Interestingly, we find that knockout of Erbin further 
increases the expression of Wnt target genes in Apc mutant tumors, which already have 
increased levels of Wnt signaling when compared to normal epithelia. While loss of 
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polarity in epithelial cells often results in decreased E-cadherin levels (as we observed in 
vitro), which could in turn result in less β-catenin sequestered to cell junctions and 
increased Wnt signaling; we observed increased Wnt signaling in Apc/Erbin KO organoids 
which maintain E-cadherin levels and an epithelial cell structure. Therefore we suspect that 
the increase in Wnt signaling after Erbin loss is not related to EMT. It has been shown 
recently that oncogenic KRAS promotes Wnt signaling through ERK-mediated 
phosphorylation of LRP6 [42]. Future studies are needed to determine if activation of ERK 
is required to mediate Erbin-dependent regulation of Wnt signaling in CRC. Alternatively, 
a straight forward study of the E-cadherin/Erbin/β-catenin complex could be performed to 
determine if Erbin is required for the formation or stability of this interaction. Using the 
Apc/KO organoids as an example, in an in vivo model it may be possible to maintain 
relatively normal levels E-cadherin after loss of Erbin, but it may be possible to 
simultaneously decrease interactions between β-catenin and E-cadherin if Erbin is 
responsible for facilitating that protein-protein interaction. Decreased β-catenin and E-
cadherin interactions would result in an increase in transcription of Wnt target genes, as 
well as an increase in “stemness” within the cell. 
In summary, our study has uncovered a pivotal role of Erbin in maintaining 
epithelial cell polarity and suppressing EMT in CRC. In addition to regulating polarity, 
Erbin disrupts the pro-signaling scaffold protein KSR1 and effectively reduces ERK 
signaling, which we have linked to increased cell motility in CRC. By developing novel in 
vivo mouse models and tumor organoid systems, we demonstrate that Erbin exerts its tumor 
suppressor function by negatively regulating both the Akt and RAF/MEK/ERK signaling 
pathways and that Erbin-loss can promote Wnt signaling and tumor initiation. Here, the 
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identification of the functional interplay between Erbin-KSR1 highlights the importance of 
scaffolding proteins in providing the spatiotemporal control of cell signals.   
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
The characterization of Erbin loss in CRC during my dissertation research, 
including the phenotypic, mechanistic, and in vivo data, answered several questions about 
the tumor suppressor role of Erbin. However, these data have also raised several more 
important mechanistic questions.  
One of the most pertinent questions raised is, how does loss of Erbin increase 
signaling in the Wnt pathway in vivo? It will be important to study this phenomenon and I 
believe that the use of the tumor organoid system that we developed will provide an 
excellent method to examine this. Future studies would involve inhibiting either the ERK 
or Akt pathways in the Apc/WT and Apc/KO organoids, then observing expression levels 
of Wnt target genes via qPCR. If either of the Erbin regulated pathways are responsible for 
the observed increase in Wnt signaling, inhibition of that particular pathway would 
decrease Wnt target gene expression levels. Conversely, if neither of the signaling 
pathways are implicated in signaling cross-talk with the Wnt pathway, Erbin may alter 
protein localization within the Wnt pathway itself. As discussed, Erbin could affect the E-
cadherin/β-catenin interaction, or it may be possible that Erbin interacts with other Wnt-
pathway proteins at the plasma membrane. We have observed that Erbin can potentially 
alter EGFR trafficking and endocytosis. Similarly, when Wnt interacts with its receptor, 
Frizzled, at the membrane, the entire Wnt signaling complex is internalized. It may be 
plausible that Erbin is generally involved in the recruitment of proteins necessary for 
receptor endocytosis and the quenching of signaling.  
Another question that has been raised during the production of these data is, how is 
Akt activated in CRC after Erbin loss? As noted, this effect seems to be cell type dependent 
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since not all studies observe increases in Akt phosphorylation when Erbin levels are 
reduced. However, it has been shown in ErbB2 over-expressing NIH3T3 cells that ErbB2 
receptor signaling to the PI3K/Akt pathway requires the involvement of the α6-β4 integrin 
[161, 162]. It may be possible that the differential effect of Erbin on the Akt pathway could 
be explained by varying levels of integrin expression between cell types. Exploring this 
possibility could be accomplished through immunoprecipitations of the ErbB2/Integrin 
interactions, with and without Erbin. Alternatively, to determine if Erbin interacts with the 
integrin in CRC, co-immunoprecipitation of Erbin with over-expressed α6-β4 integrin with 
and without the long cytoplasmic tail of β4, while simultaneously monitoring Akt 
phosphorylation, may elucidate a mechanism of action. Lastly, monitoring Akt 
phosphorylation and transiently knocking down α6-β4 integrin in sh-Erbin CRC cell lines 
could also be explored. If the integrin is involved in the necessary signal transduction to 
the Akt pathway, increases in Akt activation would be lost after the co-knockdown. 
Additionally, outside of Akt regulation, Erbin could affect cell motility through interactions 
with the α6-β4 integrin, either by altering protein stability or localization.   
Although not addressed in my studies, another potential mechanism that may 
contribute to increased tumorigenesis in Erbin knockout mice is that Erbin has been shown 
to play a role in regulating inflammation. It is well known that chronic inflammation can 
lead to increased risk for CRC and it has been suggested that Erbin loss of function can 
cause chronic inflammation [105, 108]. Paired with my observations that Erbin loss results 
in increased in vivo tumorigenesis, it would be interesting to determine if increased 
inflammation in the Apc/KO mouse model was partially responsible for tumor initiation. 
The observed increase in spleen size of the Erbin KO mice may support this idea. 
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Future studies are necessary to determine a more comprehensive understanding of 
Erbin’s role in receptor trafficking in CRC. Signaling molecules, such as EGFR, ErbB2, 
Shoc2, and KSR1, are localized in close proximity upon receptor activation. By impinging 
on signal transduction at multiple levels, Erbin could function as an effective negative 
regulator of the entire oncogenic signaling cascade. Given the changes in EGFR protein 
expression and phosphorylation in Erbin knockdown CRC cells, studying the interactions 
between EGFR or ErbB2 receptors and their adapter proteins may provide a better 
understanding for how Erbin is altering several downstream signaling pathways at the 
receptor level. Use of cell surface biotinylation and immunoprecipitation of receptors, with 
and without Erbin, could be used to understand these processes and also whether Erbin 
could alter trafficking of other RTKs. Additionally, examining the phosphorylation of 
juxtamembrane T669 of EGFR, which has been shown to be phosphorylated by ERK and 
implicated in inducing EGFR recycling, in Erbin knockdown cells may provide additional 
information on whether the recycling of EGFR is altered by Erbin-loss.  
Finally, since many of the pathways that Erbin interacts with are mutated in CRC 
development and progression, a more thorough understanding of how Erbin interacts with 
these mutant proteins is needed. Erbin loss may alter the protein interaction networks and 
possibly how oncogenic proteins such as KRAS interact with downstream partners. 
Observations of increased BRAF protein levels after Erbin knockdown in several CRC cell 
lines may suggest that the loss of this scaffold protein could alter protein stability due to 
changes in protein-protein interactions. With this in mind, many of the proteins within the 
Erbin signaling network are currently targeted with cancer therapeutics. Understanding the 
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protein interactions and consequences of Erbin loss may allow us to explore the potential 
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APPENDICES 
Appendix: List of Acronyms and Abbreviations  
18q Long arm of 18th chromosome 
2D Traditional 2-dimensional cell culture 
3D 3-dimensional cell culture 
AJ Adherens Junction 
Akt Protein Kinase B 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
AMPK AMP-activated protein kinase 
APC Adenomatous polyposis coli  
ARVCF Armadillo repeat protein deleted in velo-cardio-facial syndrome  
BSA Bovine Serum Albumin 
CFP Cyan Fluorescent Protein 
CIN Chromosomal Instability pathway 
CRC Colorectal Cancer 
DCC Deleted in Colon Cancer  
DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic Acid 
DSG1 Desmoglein-1 
eBPAG1 Bullous pemphigoid antigen 1 
ECL Enhanced chemiluminescence 
EdU 5-ethynyl-2’-deoxyuridine 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor (ErbB1) 
EMT Epithelial to Mesenchymal Transition 
ERK Extracellular signal-regulated kinase 
FAP Familial adenomatous polyposis 
FBS Fetal Bovine Serum 
Flag Synthetic peptide tag – peptide sequence: DYKDDDDK 
G1 Gap 1 phase of cell cycle 
G2  Gap 2 phase of cell cycle 
GDC0941 Pictilsib, Akt inhibitor 
Grb2 Growth factor receptor-bound protein 2 
GSEA Gene Set Enrichment Analysis 
GTP Guanosine triphosphate 
H&E Hematoxylin and eosin stain 
HEPES Hydroxyethyl piperazineethanesulfonic acid  
HSP90 Heat shock protein 90 
IgE Immunoglobulin E 
IHC Immunohistochemical Staining 
kb Kilobase 
kDa Kilodalton 
KO Knockout of a gene 
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KSR1 Kinase suppressor of Ras1 
LAP LRR and PDZ containing protein 
Lef Lymphoid enhancer factor 
LGR-4/5 Leucine rich repeat containing G protein-coupled receptor 4 or 5 
LKB1 Liver kinase B1 
LOH Loss of Heterozygosity  
LPS Lipopolysaccharides 
LRP6 Low-density lipoprotein receptor-related protein 6 
LRR Leucine Rich Repeats 
M Mitotic phase of cell cycle 
MAPK Mitogen-activated protein kinases 
MEF Mouse Embryonic Fibroblast cells 
MH2 MAD homology 2 
MK2206 Akt Inhibitor 
MMR Mismatch repair 
mRNA Messenger RNA 
MSI Microsatellite Instability  
Myc Synthetic peptide tag – peptide sequence: EQKLISEEDL 
NFκB Nuclear factor κB 
NMR Nuclear magnetic resonance 
Nod2 Nucleotide-binding oligomerization domain-containing protein 2 
p21 Cyclin-dependent kinase inhibitor 1 
p27 Cyclin-dependent kinase inhibitor 1B 
PAS Periodic acid-Schiff 
PBS Phosphate Buffered Saline 
PD184352 MEK1/2 inhibitor 
PD98059 MEK1 inhibitor 
PEI Polyethylenimine 
PICK1 Protein interacting with C kinase - 1 
PDZ PSD94/Dlg1/ZO-1 domain 
PTB Phosphotyrosine-binding domain 
qPCR Reverse transcriptase quantitative polymerase chain reaction 
RNA Ribonucleic acid 
RNA-seq RNA sequencing for quantity of RNA in a biological sample 
RTK Receptor Tyrosine Kinase 
S Synthesis phase of cell cycle 
SARA Smad anchor for receptor activation 
SEM Standard Error of the Mean 
SH2 Src homology 2 domain 
SH3 Src homology 3 domain 
SHC Src homology and collagen 
ShRNA Short hairpin RNA 
SOS Son of Sevenless 
SPPK Striate palmoplantar keratoderma 
Stat3 Signal transducer and activator of transcription 3 
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Tcf T-cell Factor 
TCGA The Cancer Genome Atlas 
TGFβ Transforming growth factor beta 
TMA Tissue microarray 
TNFα Tumor necrosis factor alpha 
TP53 Gene for Tumor protein p53 
U0126 MEK1/2 inhibitor 
Vil-Cre Cre recombinase driven by the villin 1 promoter 
WT Wildtype 
ZO-1 Zonula occludens-1 
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